PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 1TITLE PAGE
Protocol Title: Single -Arm Study  of Lorlatinib in Participants with Anaplastic Ly mphoma 
Kinase (ALK) -Positive Non- Small Cell L ung Cancer (NSCL C) Whose Disease Progressed 
After One Prior Second -Generation ALK Ty rosine Kinase Inhibitor (TKI)
Protocol Number: B7461027
Amendment Number: Not applicable
Compound Number: PF-06463922
Study Phase: Phase 4
Short Title: Study  of Lorlatinib In Participants with Anaplastic Ly mphoma Kinase 
(ALK) -Positive NSCL C
Acronym: Not Applicable
Sponsor Name: [CONTACT_4618], Inc
Legal Registered Address: [ADDRESS_676057], [LOCATION_001], NY [ZIP_CODE]- 5755, [LOCATION_003]
Regulatory Agency Identifier Number(s)
Registry ID
IND 118,[ADDRESS_676058] 2019 -002504 -41
Approval Date: 22 January 2020
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) or 
use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfize r 
must be promptly notified.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 22Jan2020
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676059] OF TABLES .....................................................................................................................6
1. PROTOCOL  SUMMARY .....................................................................................................7
1.1. Sy nopsis ....................................................................................................................7
1.2. Schema ....................................................................................................................11
1.3. Schedule of Activ ities (SoA) ...................................................................................12
1.3.1. Screening and C ycle1
................................................................................12
1.3.2. Visits on Day 1 of Every  Other C ycle (up to 35 cycles and 
>35cycles) .......................................................................................................14
1.3.3. End of Treatment and Follow -Up...............................................................16
2. INTRODUCTION ...............................................................................................................18
2.1. Study  Rationale .......................................................................................................19
2.2. Background .............................................................................................................19
2.3. Benefit/Risk Assessment
.........................................................................................19
3. OBJECTI VES, ESTIMANDS
AND ENDPOINTS ............................................................20
4. STUDY DESIGN .................................................................................................................22
4.1. Overall Design .........................................................................................................22
4.2. Scientific Rationale for Study  Design .....................................................................23
4.3. Justification for Dose ..............................................................................................23
4.4. End of Study  Definition ..........................................................................................23
5. STUDY POPUL ATION
......................................................................................................23
5.1. I nclusion Criteria .....................................................................................................23
5.2. Exclu sion Criteria ....................................................................................................26
5.3. L ifesty le Considerations ..........................................................................................28
5.4. Screen Failures ........................................................................................................29
6. STUDY INTERVENTIO N
................................ ................................ ................................ ..29
6.1. Study  Intervention(s) Administered ........................................................................29
6.2. Preparation/Handling/Storage/Accountability ........................................................29
6.3. Measures to Minimize Bias: Randomization and Blinding ................................ .....31
6.4. Study  Intervention Compliance ...............................................................................31
6.5. Concomitant Therapy ..............................................................................................31
6.5.1. P rohibited Concomitant Treatments ...........................................................31
6.5.2. Permitted Concomitant Treatments ................................ ............................ 33
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 46.6. Dose Modification ...................................................................................................36
6.7. I ntervention after the End of the Study ...................................................................39
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................39
7.1. Discontinuation of Study  Intervention ....................................................................39
7.1.1. Temporary  Discontinuation ........................................................................40
7.2. Participant Discontinuation/Withdrawal from the Study ........................................[ADDRESS_676060] to Follow up
....................................................................................................41
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................42
8.1. Efficacy  Assessments ..............................................................................................43
8.1.1. Tumor Assessments ....................................................................................43
8.2. Saf ety Assessments .................................................................................................43
8.2.1. Phy sical Examinations ................................................................................43
8.2.2. Electrocardiograms
.....................................................................................44
8.2.3. Echocardiograms/Multigated (MUGA) Acquisition Scan .........................44
8.2.4. ECOG Performance Status .........................................................................44
8.2.5. Clinical Safety  Laboratory  Assessments ....................................................44
8.2.6. Pregnancy  Testing ......................................................................................45
8.3. Adverse Events and Serious Adverse Events..........................................................45
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......46
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................46
[IP_ADDRESS]. Recording Non -serious AEs and SAEs on the CRF .................47
8.3.2. Method of Detecting AEs and SAEs ..........................................................47
8.3.3. Follow -up of AEs and SAEs .......................................................................47
8.3.4. Regulatory
 Reporting Requirements for SAEs ................................ ........... 47
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................48
[IP_ADDRESS]. Exposure During Pregnancy ......................................................48
[IP_ADDRESS]. Exposure During Breastfeeding ................................................48
[IP_ADDRESS]. Occupational Exposure .............................................................48
8.3.6. Medication Errors .......................................................................................49
8.4. Treatment of Overdose
............................................................................................49
8.5. Pharmacokinetics ....................................................................................................50
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 58.6. Pharmac odynamics ..................................................................................................50
8.7. Genetics ...................................................................................................................50
8.7.1. Specified Genetics ......................................................................................50
8.7.2. Banked Biospecimens for Genetics ............................................................50
8.8. Biomarkers ..............................................................................................................50
8.9. Health Economics ...................................................................................................50
9. STATI STICAL CONSI DERATIONS
................................................................................50
9.1. Estimands and Statistical Hy potheses .....................................................................50
9.1.1. Estimands ....................................................................................................51
9.2. Sample Size Determination .....................................................................................52
9.3. Populations for Analyses .........................................................................................52
9.4. Statistical Analy ses.................................................................................................53
9.4.1. E fficacy  Anal yses.......................................................................................53
9.4.2. Safet y Anal yses..........................................................................................56
9.5. I nterim Anal yses.....................................................................................................57
9.5.1. Data Monitoring Committee (DMC)
..........................................................57
9.5.2. I ndependent Central Radiological Review .................................................57
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................58
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversig ht Considerations ...............58
10.1.1. Regulatory  and Ethical Considerations ....................................................58
10.1.2. Financial Disclosure .................................................................................59
10.1.3. I nformed Consent Process ........................................................................59
10.1.4. Data Protection .........................................................................................60
10.1.5. Committees Structure ................................ ................................ ............... 60
10.1.6. Dissemination of Clinical Study  Data ................................ ...................... 60
10.1.7. Data Qualit y Assurance ............................................................................61
10.1.8. Source Documents ....................................................................................63
10.1.9. Study  and Site Closure ................................ ................................ .............. 63
10.1.10. Publication Policy ................................ ................................ ................... 64
10.1.11. Sponsor’s Qualified Medical Personnel ................................ ................. 64
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................66
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 610.3. Appendix 3: Adverse Events: Definiti ons and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................68
10.3.1. Definition of AE .......................................................................................68
10.3.2. Definition of SAE
.....................................................................................69
10.3.3. Recording/Reporting and Follow- Up of AE and/or SAE .........................70
10.3.4. Reporting of SAEs
....................................................................................73
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy  
Information ................................................................................................................75
10.5. Appendix 5: RECIST (version 1.1) Tumor Assessment Criteria21.......................78
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments ........84
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................86
10.8. Appendix 8: Country -specific Requirements ........................................................88
10.9. Appendix 9: ECOG Classification of Performance Status ....................................89
10.10. Appendix 10: Abbreviations ...............................................................................[ADDRESS_676061] OF TABLES
Table 1.
Pharmacokinetic Properties of Statins......................................................34
Table 2. Pharm acokinetic properties of L ipid Lowering Agents ............................35
Table 3. Recommended Lorlatinib Dose Modifications for Adverse 
Reactions ...................................................................................................36
Table 4. Protocol Required Safet y Laboratory  Assessments ..................................66
Table 5. Response Evaluation Criteria in Solid Tumors
........................................82
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 71.PROTOCOL SUMMARY
1.1.Synopsis
Protocol Title: Single -Arm Study  of Lorlatinib in Participants with Anaplastic Ly mphoma 
Kinase (ALK) -Positive Non- Small Cell L ung Cancer (NSCL C) Whose Disease Progressed 
After One Prior Second -Generation ALK Ty rosine Kinase Inhibitor (TKI)
Short Title: Study  of Lorlatinib I n Participants with Anaplastic Ly mphoma Kinase 
(ALK) -Positive NSCL C
Rationale:
On the basis of pi[INVESTIGATOR_9205] 1/2 study  B746 1001, lorlatinib received Conditional Marketing 
Authorization (CMA) by [CONTACT_521285] (EMA) on 7 May 2019 for the 
treatment of patients with ALK- positive metastatic non -small -cell lung cancer whose disease 
has progressed after: 
alectinib or ceritinib as the first ALK t yrosine kinase inhibitor (TKI) therapy; or
crizotinib and at least one other ALK inhibitor. 
However, in view of the limited sample size of [ADDRESS_676062] second generation ALK TKI 
from the pi[INVESTIGATOR_30338] 1/2 study  B7461001, in addition to the ongoing Phase 3 study  
B7461006 (CROWN), the EMA requested a post -authorization efficacy  study  (PAES) to 
obtain additional data on the activity of lorlatinib in the second -line setting .
Objectives, Estimands and Endpoints
Objectives Estimands Endpoints
Primary  
To assess Overall and 
Intracranial Response 
Rate of single -agent 
lorlatinib in participants 
with advanced 
ALK -positive NSCL C 
whose disease has 
progressed on alectinib 
or ceritinib as the first 
ALK ty rosine kinase 
inhibitor (TKI) therap yThe primary  estimand is 
the treatment effect of 
lorlatinib by  [CONTACT_69798] ( ICR
)
from time of first dose 
until progression is met 
or subsequent anti -
cancer therap y is 
administered for all 
participants who receive 
at least one dose of 
lorlatinib without regard 
to discontinuation from 
treatmentConfirmed Objective 
Tumor Response 
assessed b y Response 
Evaluation Criteria in 
Solid Tumor (RECI ST) 
version 1.1 per ICR
Secondary
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 8To assess secondary  
measures of clinical 
efficacyThe estimand for 
Objective Response 
(OR)by [CONTACT_1697] 
(INV) follows the 
estimand specified for 
the primary  endpoint
except that the treatment 
effect is based on INV
The estimand for 
Intracranial ( IC)
response is the 
Intracranial treatment 
effect (ie in brain 
lesions) of lorlatinib 
from time of first dose 
until I ntracranial 
progression is met or 
subsequent anti -cancer 
therap y is administered 
for all participants who 
receive at least one dose 
of lorlati nib without 
regard to discontinuation 
from treatment
The estimand for Time 
to Tumor Response 
(TTR )is the treatment 
effect from the time of 
first dose to the first date 
ofresponse that is 
subsequently  confirmed 
for responders to 
lorlatinib
The estimand for 
Duration of Response 
(DOR )is the treatment 
effect from the first date 
of OR that is 
subsequently  confirmed 
for responders to 
lorlatinib until 
progression or death, 
without regard to 
discontinuation from Every  endpoint assessed 
by [CONTACT_274219] 1.1
Confirmed Objective 
Tumor Response 
assessed b y INV
Confirmed I ntracranial 
tumor response assessed 
per ICR and INV
TTR per ICR and INV
DOR per ICR and INV
Duration of Intracranial 
response (I C-DOR) per 
ICR and INV
TTP per ICR and INV
PFS per ICR and INV
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 9treatment unless new 
anti-cancer therap y is 
initia ted or extended gap 
in tumor assessment is 
present prior to 
progression or death
The estimand f or 
IC-DOR follows the 
estimand specified for 
the DOR, but limited to 
intracranial lesions
The estimand for Time 
to Tumor Progression 
(TTP)is the treatment 
effec t from the time of 
first dose for all 
participants who receive 
at least one dose of 
lorlatinib until 
progression, without 
regard to discontinuation 
from treatment un less 
participant dies, new 
anti-cancer therap y is 
initiated or extended gap 
in tumor assessment is 
present prior to 
progression
The estimand for 
Progression Free 
Survival ( PFS)is the 
treatment effect from the 
time of first dose for all 
participants who receive 
at least one dose of 
lorlatinib until 
progression or death, 
without regard to 
discontinuation from 
treatment unless new 
anti-cancer therap y is 
initiated or an extended 
gap in tumor assessment 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 10is present prior to 
progression or death
To confirm the safet y 
and tolerability  of 
lorlatinibThe estimand for safet y 
is the incidence of 
Adverse Events from the 
time of first dose to 
28days post last dosing 
date or the date of 
initiation of a new anti -
cancer therapy  for all 
participants who receive 
at least one dose of 
lorlatinibAdverse Events a s 
characterized b y type, 
frequency , severity  (as 
graded b y National 
Cancer Institute 
Common Terminology  
Criteria for Adverse 
Events [NCI  CTCAE] 
v.4.03), seriousness, and 
relationship to study  
therap y
Overall Design:
This is a Phase [ADDRESS_676063] line of treatment for metastatic disease.
Disclosure Statement :
This is a Single Group Treatment study  with 1Arm that has No masking .
Number of 
Participant s:
Approximately  85participants will be screened to achieve 70participants assigned to study  
intervention. 
Intervention Groups and Duration:
Participants will take lorlatinib at the approved dose of 100 mg QD (once daily ). Participants 
will be treated until disease progression, participant refusal/lost to follow- up, or unacceptable 
toxicity .
Data Monitoring Committee: No
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 111.2.Schema
aalectinib or certinib
bTreatment until disease progression, patient refusal/lost to follow -up, or unacceptable toxicity.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 121.3.Schedule of Activities (SoA)
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to Section 8 of the protocol for 
detailed information on each assessment required for compliance with the protocol.
The Investigator may  schedule visits (unplanned visits) in addition to those listed in the schedule of activities table in or der to conduct 
evaluations or assessments required to protect the well- being of the participant.
1.3.1. Screening and Cycle 1
Visit Identifier Screening* Cycle 1
(21days)Notes
*to be obtained w ithin 28 days prior to registration
Visit Window ≤28 days Day 1
(±1day)(X) refer to specific footnote when the measurement may be optional /repeat 
measurement might not be required.
Informed consent X Must be obtained prior to undergoing any study specific procedures that are not 
considered standard of care.
Tumor history X
Medical history X Data on prior anti -cancer therapy will be collected along with the best -known response 
from the previous ALK inhibitor.
Physical examination X X
Weight X X
Performance Status X X
Contraception check (as 
appropriate)X
Laboratory
Hem atology X (X) No need to repeat on C1D1 if baseline assessment performed w ithin [ADDRESS_676064] information. 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 13Visit Identifier Screening* Cycle 1
(21days)Notes
*to be obtained w ithin 28 days prior to registration
Visit Window ≤28 days Day 1
(±1day)(X) refer to specific footnote when the measurement may be optional /repeat 
measurement might not be required.
Blood Chemistry X (X) No need to repeat on C1D1 if baseline assessment performed w ithin [ADDRESS_676065] X (X) For fe male participants of childbearing potential, a serum or urine pregnancy test will be 
performed once at the start of screening and once at the baseline visit, immediately 
before study intervention administration.  The pregnancy test should be performed at t he 
clinical site’s local laboratory.
Cardiac Monitoring
12-lead ECG X (X) No need to repeat on C1D1 if baseline assessment performed w ithin [ADDRESS_676066] 
information.
For [LOCATION_009] and [LOCATION_013], a transthoracic echocardiogram (TTE) w ill be performed 
every 6 months ( ±2 weeks) during treatment, and only at the end of treatment visit if the 
previous assessment was > 1 month. Pulmonary arterial pressure (PAP) w ill be assessed.
Registration
Registration (X) Registration will be within [ADDRESS_676067] Abdomen Pelvis [CAP] and MRI of the brain will be performed at screening.  
Bone scans (or bone MRI if preferred by [CONTACT_1697]) w ill be performed at baseline fo r 
all participants and repeated every 12 weeks on study only if evidence of bone 
metastases is observed at baseline.  
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 14Visit Identifier Screening* Cycle 1
(21days)Notes
*to be obtained w ithin 28 days prior to registration
Visit Window ≤28 days Day 1
(±1day)(X) refer to specific footnote when the measurement may be optional /repeat 
measurement might not be required.
Cerebrospi[INVESTIGATOR_521275]/carcinomatous 
meningitis [LM/CM] disease is 
presentXCSF is mandatory for participants who have asym ptomatic radiologically suspected 
leptomeningeal disease (LM) or carcinomatous meningitis (CM) but negative spi[INVESTIGATOR_13858].
Other Clinical Assessments
Adverse Events X XFor AEs and SAEs , the active reporting period to [COMPANY_007] or its designated representative 
begins from the time that the participant provides informed consent, which is obtained 
prior to the participant ’s participation in the study through and including a minimum of 
28calendar days after the last administration of the study intervention .  Refer to 
Section 8.3.1 for all specifications .
Concomitant medications and non -
drug supportive interventionsX X
1.3.2. Visits on Day 1 of Every Other Cycle (up to 35 cycles and >35 cycles)
Visit Identifier Visits on Day 1 
of Every Other 
Cycle up to 
35cycles (up to 
24months)Visits on Day 1 
of Every Other 
Cycle 
(>35cycles or 
24months)Notes
(X) refer to specific footnote when the measurement may be optional /repeat 
measurement might not be required.
Visit Window ±4days ±4days
Physical examination X
Weight X
Contraception check (as 
appropriate)X
(every cycle 
±2days)X
(every cycle 
±2days)At cycle not requiring site visit the participant may be contact[CONTACT_521286].  
Laboratory
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 15Visit Identifier Visits on Day 1 
of Every Other 
Cycle up to 
35cycles (up to 
24months)Visits on Day 1 
of Every Other 
Cycle 
(>35cycles or 
24months)Notes
(X) refer to specific footnote when the measurement may be optional /repeat 
measurement might not be required.
Visit Window ±4days ±4days
Pregnancy test X
(every cycle 
±2days)X
(every cycle 
±2days)Pregnancy tests will be routinely repeated at every cycle (±2 days) during the active 
treatment period and additionally whenever one menstrual cycle is missed or when 
potential pregnancy is otherwise suspected.  The pregnancy test should be 
performed at the clinical site’s local laboratory .  Where that is not possible, 
participants will provide the laboratory test results carried out at a non -clinical site 
laboratory, eg, by [CONTACT_756], and bring a copy of the laboratory test results at the 
next cycle visit.  The copy of the laboratory test results must be retained in the 
participants’ file at the clinical site for documentation purposes.
Study Intervention
Study Intervention Once a day continuously
Tumor Assessments
CT and MRI Scan or 
Equivalent(every 6 weeks ± 
1week)(As per local 
clinical practice)CT and MRI scans to be done at every 6 weeks ±1 w eek up to approximately 24 
months (cycle 35) and then as per local clinical practice.
Other Clinical Assessments
Adverse Events X X
Concomitant medications and 
non-drug supportive 
interventionsX All concomitant medications and non -drug supportive interventions should be 
recorded in the CRF until the participant has completed 35 cycles of treatment 
(approximately 24 months).  After cycle 35 the data will be reported in the medical 
chart, but not collected in the CRF.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 161.3.3. End of Treatment and Follow -Up
End of Treatment Visit: Obtain these assessments if not completed in the last week (last 6 weeks for tumor assessments up to 
24months).  
Follow up: At least [ADDRESS_676068] every 4 weeks until resolution or determination, in the clinical judgment of the 
Investigator, that no further improvement is expected.  Participants discontinuing treatment for reasons other than prog ression of 
disease will continue to perform tumor assessments until PD up to approximately  24months (cy cle35).
Visit Identifier End of 
Treatm entFollow -up Notes
(X) refer to specific footnote when the measurement may be optional /repeat 
measurement might not be required.
Visit Window ±2days ±7days
Physical examination X
Weight X
Contraception check (as 
appropriate)X X The participant may be contact[CONTACT_521287].  Males and females of childbearing potential must be 
contact[CONTACT_521288] [ADDRESS_676069] should be performed at the clinical site’s local laboratory.  
Where that is not possible, participants will provide the laboratory test results 
carried out at a non -clinical site laboratory, eg, by [CONTACT_756], and brin g a copy of 
the laboratory test results at the next cycle visit.  The copy of the laboratory test 
results must be retained in the participant’s file at the clinical site for 
documentation purposes.
Tumor Assessments
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 17Visit Identifier End of 
Treatm entFollow -up Notes
(X) refer to specific footnote when the measurement may be optional /repeat 
measurement might not be required.
Visit Window ±2days ±7days
CT and MRI Scan or 
Equivalent(X)Tumor assessment should be repeated at the end of treatment if more than [ADDRESS_676070] evaluation. Tumor assessment should not be repeated at 
the end of treatment if progression occurs when the participant has shifted to the 
local clin ical practice.
Other Clinical Assessments
Adverse Events X X
Concomitant medications and 
non-drug supportive 
interventions(X)
Abbreviations: AE = adverse events; CAP = Chest abdomen pelvis; c; CNS = central nervous system; CT = computed tomography; CR F = case report form; 
CSF = cerebrospi[INVESTIGATOR_872]; C1D1 = cycle 1 day 1; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; LM = leptomeningeal 
meningitis; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; MUGA = multigated acquisition; NCI C TCAE = National Cancer 
Institute common terminology criteria for adverse events; PD = progression of di sease; RECIST = Response Evaluation Criteria in Solid Tumors; TTE = 
transthoracic echocardiogram
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676071] common cancers in the world (2.1 million new cases 
estimated in 2018), 12% of all new can cers wor ld-wide.1Non-small cell lung cancer 
(NSCL C) constitutes ap proximately  85% of all lung cancer.
In 2007, two research groups independently  reported the discovery  of an NSCL C oncogenic 
fusion gene (echinoderm microtubule -associated protein -like 4 [ EML 4]-ALK) that combines 
portions of the EML 4
gene and the anaplastic l ymphoma kinase (ALK) gene.2, 3  This fusion 
gene encodes for the cy toplasmic fusion protein EML 4-ALK which upon dimerization, 
results in constitutive a
ctivation of the kinase domain of ALK. Approximately  3-5% of 
NSCL C is histologically  defined as ALK+4and the vast majority  of ALK fusion positive 
cases were observed in young, non -
smoking patients with lung adenocarcinoma, and are 
rarely coincident with c-ROS oncogene -1 (ROS1 ), epi[INVESTIGATOR_3506] ( EGFR ) , 
human epi[INVESTIGATOR_3506] 2 (HER2) , or Kirsten Rat Sarcoma ( KRAS )
mutations.[ADDRESS_676072] participants with AL K-positive NSCL C derive substantial clini cal benefit 
from crizotinib and the second generation ALK -TKIs alectinib and ceritinib5-8, some 
participants will not respond to treatment (intrinsic resistance), and other participants who 
initially  experience clinical benefit will later develop resistance (acquired resistance) or 
develop disease progression in the central nervous sy stem (CNS).9, 
[ADDRESS_676073]-or second -line setting, chemotherap y and/or immunotherapy  would be the fall back 
standard of care. 
Outcomes with chemotherap y alone 
have been modest. I n a randomized Phase 3 trial of 
ceritinib vs chemotherapy  (docetaxel or pemetrexed) in patients with ALK -positive NSCL C 
who had been previous ly treated with chemotherapy  and crizotinib, chemotherapy  had an 
objective response rate (ORR) of 6.9% and median PFS of 1.6 months, as determined b y 
blinded I CR. Chemotherapy  also has a limited intracranial (IC) ORR even in a treatment-
naïve setting.  In a randomized Phase [ADDRESS_676074] an IC ORR b y ICR of 21.2% (95% confidence interval [CI ]: 11.1, 34.7).[ADDRESS_676075] line ALK- TKI (atezolizumab11) or a s monotherap y in patients whose tumors
express PD -L1 with a ≥ 1% tumor proportion score ( TPS)and who have received at least one 
prior chemotherap y regimen and a target therap y (pembrolizumab12).
Although, these treatments have shown very promising results13, 14, few patients with AL K 
positive tumors were enrolled and conclusive results in this specific subpopulation are still 
warranted.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676076]- generation ALK TKI lorlatinib offers a therapeutic 
option active in this setting.
2.1.Study Rationale
On the basis of pi[INVESTIGATOR_9205] 1/2 B7461001, lorlatinib received CMA b y the European 
Medicine Agency  (EMA) on 7 May 2019 for the treatment of participants with AL K-positive 
metastatic non -small -cell lung cancer whose disease has progressed a fter: 
alectinib or ceritinib as the first ALK t yrosine kinase inhibitor (TKI) therapy; or
crizotinib and at least one other ALK inhibitor. 
However, in view of the limited sample size of [ADDRESS_676077] second generation ALK 
TKI from the pi[INVESTIGATOR_312847] e 1/2 study  B7461001, in addition to the ongoing Phase 3 study  
B7461006 (CROWN), the EMA requested a PAES to obtain additional data on the activit y of 
lorlatinib in the second -line setting .
2.2.Background
Lorlatinib is a highl y potent, selective third -generation ty rosine kinase inhibitor directed at 
the ALK and c-ros oncogene 1 (ROS1) kinases.  Using structure -based drug design, this 
macrocy clic ty rosine kinase inhibitor was developed to retain potency  against most known 
ALK resistance mutations and to penetrate the blood –brain barrier.  Lorlatinib demonstrated 
marked antitumor activity  in mice bearing tumor xenografts that express echinoderm 
microtubule -associated protein -like 4 (EML4) fusions with AL K variant 1 (v1), including 
ALK mutations L 1196M, G12
69A, G1202R, and I1171T. Two of these ALK mutants, 
G1202R and I1171T, are known to confer resistance to alectinib, brigatinib, ceritinib, and 
crizotinib. Lorlatinib was also capable of penetrating the blood- brain barrier and 
demonstrated activity  in mice bearing orthotopic EML 4-ALK or EML4 - ALKL1196M brain 
tumor implants.
In the pi[INVESTIGATOR_119229] -arm, multicenter Phase [ADDRESS_676078] 1 ALK t yrosine kinase 
inhibitor, including the second -generation drugs ceritinib and alectinib.  In the cohort of 
participants previousl y treated with a second generation ALK -TKI, a high proportion o f 
participants achieved an OR (12 [42.9%] of 28) and durable responses ( median duration of 
response 5.6 months [95% CI  4.2–not reached]). 
Substantial intracranial activity  was also observed in these participants suffering from 
frequent brain metastases. T
he proportion of participants with objective intracranial response 
to lorlatinib was 66.7% in participants with at least one measurable brain lesion at baseline.
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits an d risks and reasonabl y 
expected adverse events (AEs) of lorlatinib may  be found in the Summary  of Product 
Characteristics (SmPC) , which is the single reference safet y document (SRSD) for this study. 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 203.OBJECTIVES, ESTIMAND S AND ENDPOINTS
Objectives Estima nds Endpoints
Primary
To assess Overall and 
Intracranial Response 
Rate of single -agent 
lorlatinib in participants 
with advanced ALK -
positive NSCL C whose 
disease has progressed on 
alectinib or ceritinib as 
the first ALK t yrosine 
kinase inhibitor (TKI) 
therap yThe primary  estim and is 
the treatment effect of 
lorlatinib by [CONTACT_521289] ( ICR
)from 
time of first dose until 
progression is met or 
subsequent anti -cancer 
therap y is administered 
for all participants wh o 
receive at least one dose 
of lorlatinib without 
regard to discontinuation 
from treatmentConfirmed Objective 
Tumor Response assessed 
by [CONTACT_521290] 
(RECI ST) version 1.1 per 
ICR
Secondary
To assess secondary  
measures of clinical 
efficacy  The estimand for 
Objective Response (OR)
by [CONTACT_1697] (INV)
follows the estimand 
specified for the primary  
endpoint except that the 
treatment effect is based 
on INV
The estimand for 
Intracranial ( IC)response 
is the I ntracranial 
treatment effect (ie in 
brain lesions) of 
lorlatinib 
from time of first dose 
until I ntracranial 
progression is met or 
subsequent anti -cancer 
therap y is administered 
for all participants wh o 
receive at least one dose 
of lorlatinib without 
regard to discontinuation 
from treatme ntEvery  endpoint assessed by  
[CONTACT_521291] 1.1
Confirmed Objective 
Tumor Response assessed 
by [CONTACT_521292]
Confirmed Intracranial 
tumor response assessed per 
ICR andINV
TTR per ICR and INV
DOR per ICR and INV
Duration of Intracranial 
response (I C-DOR) per ICR
and INV
TTP per ICR and INV
PFS per ICR and INV
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 21The estimand for Time to 
Tumor Response ( TTR )is 
the treatment effect from 
the time of first dose to 
the first date of response 
that is subsequently  
confirmed for responders 
to lorlatinib
The estimand for 
Duration of Response 
(DOR )is the treatment 
effect from the first date 
of OR that is 
subsequently  confirmed 
for responders to 
lorlatinib until 
progression or death , 
without regard to
discontinuation from 
treatment unless new 
anti-cancer therap y is 
initiated or extended gap 
in tumor assessment is 
present prior to 
progression or death
The estimand for IC -DOR 
follows the estimand 
specified for the DOR, 
but limited to intracranial 
lesions
The estimand for Time to 
Tumor Progression ( TTP)
is the treatment effect 
from the time of first dose 
for all participants who 
receive at least one dose 
of lorlatinib until 
progression, without 
regard to discontinuation
from treatment unless 
participant dies, new anti -
cancer therap y is initiated 
or extended gap in tumor 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 22assessment is present
prior to progression
The estimand for 
Progression Free Survival 
(PFS)is the treatment 
effect from the time of 
first dose for all 
participants who receive 
at least one dose of 
lorlatinib until 
progression or death , 
without regard to 
discontinuation from 
treatment unless new anti -
cancer therapy  is initiated 
or an extended gap in 
tumor assessment is 
present prior to 
progression or death
To confirm the safet y and 
tolerability  of lorlatinibThe estimand for safet yis 
theincidence of Adverse 
Events from the time of 
first dose to [ADDRESS_676079] one dose of 
lorlatinibAdverse Events as 
characterized b y type, 
frequency , severity  (as 
graded b yNational Cancer 
Institute Common 
Terminology  Criteria for 
Adverse Events [NCI  
CTCAE] v.4.03 ), 
seriousness, and 
relationship to study  
therap y
This protocol will use an independent endpoint adjudication committee to determine whether 
certain investigato r-reported events meet the definition of disease -related efficacy  endpoints, 
using predefined endpoint criteria (see Section 9.5.2 ).  
4.STUDY DESIGN
4.1.Overall Design
This is a Phase [ADDRESS_676080] line of treatment for metastatic disease.  
Approximately  85participants will be screened to achieve 70participants assigned to study  
intervention .  
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676081] 1.1 , participant refusal/lost to follow -up, or 
unacceptable toxicity .
4.2.Scientific Rationale for Study Design
The pi[INVESTIGATOR_30338] 1/[ADDRESS_676082] line treatment .  In order to allow for a 
more precise estimation of the 95% confidence interval (CI) of the primary endpoint the 
proposed study increases the sample size in this population .
4.3.Justification for Dose
The dose of 100 mg QD is the approved dose based on the safet y and efficacy data provided 
by [CONTACT_165894] 1 portion of pi[INVESTIGATOR_2397]  B7461001.
4.4.End of Study Definition
The End of Tri al is defined as 12 calendar months after the “last patient first visit” (L PFV) 
date in the study .
Participants who still experience clinical benefit at the End of Trial will discontinue from the 
study  and continue treatment per standard of care (SOC). A n umber of options for ensuring 
continued supply  with lorlatinib will be considered based on the local availability  of the 
treatment and local country  laws/regulation.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant
s are enrolled.  The 
following eligibility  criteria are designed to select participants for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol.  Participant eligibility  should be reviewed and documented by  [CONTACT_36534] y 
qualified member of the investigator’s study  team before participants are included in the 
study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age
1. Participant must be ≥18 years of age inclusive (or ≥20 years of age if required by  
[CONTACT_1295]), at the time of signing the informed consent.
Type of Participant and Disease Characteristics
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676083] evidence of histologicall y or cytologically  confirmed 
diagnosis of metastatic NSCL C (Stage IV, American Joint Committee on Cancer 
[AJCC]v7.0) that carries an ALK rearrangement, as determined b y the Food and 
Drug Administration (FDA) approved fluorescence in situ hy bridization (FISH ) assay 
(Abbott Molecular Inc) or by  [CONTACT_51719]  (IHC) (Ventana Inc).
3.Disease Status Requirements: d isease progression after alectinib or ceritinib as first 
line therap y (the stud y will limit enrollment of participants with best response of 
progressi on or indeterminate on prior alectinib to 8 participants).  Participants may  
have had prior chemotherap
y, but only if before starting treatment with alectinib or 
ceritinib.
4.Tumor Requirements: All Participants must have at least one measurable target 
extra cranial lesion according to RECI ST v1.1.  Participants with as ymptomatic CNS 
metastases (including participants controlled with stable or decreasing steroid use 
within the last 2 weeks prior to study  entry ) will be eligible.  The brain metastases 
may be ne wly diagnosed or be present as progressive disease after surgery, whole 
brain radiotherap y or stereotactic radiosurgery.  Participants who have 
leptomeningeal disease (LM) or carcinomatous meningitis (CM) will be eligible if the 
LM/CM is visualized on magn etic resonance imaging ( MRI )or if documented 
baseline cerebral spi[INVESTIGATOR_872] (CSF) positive cy tology  is available.
5.Eastern Cooperative Oncology  Group (ECOG) Performance Status (PS) 0 or 1.
6. Adequate bone marrow functioning, including:
a.Absolute Neutrophil Count (ANC) ≥1,500/mm3or ≥1.5 x 109/L;
b.Platelets ≥100,000/mm3or ≥100 x 109/L;
c.Hemoglobin ≥9 g/dL.
7. Adequate pancreatic function, including:
a.Serum total amy lase ≤1.5 x upper limit of normal (ULN)*;
b.Serum lipase ≤1.[ADDRESS_676084].
*if total amy lase >1.[ADDRESS_676085], but p ancreatic amylase is within the UL N, the 
participant may be enrolled.
8.Adequate renal function, including:
a.Serum creatinine ≤1.[ADDRESS_676086] or estimated creatinine clearance ≥60 mL /min 
as calculated using the method standard for the institution.
9.Adequate liver function, including:
a.Total serum bilirubin ≤1.[ADDRESS_676087]; 
b.Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.[ADDRESS_676088] ( ≤5.0 x UL N in case of liver metastases).
10.Acute effects of an y prior therap y resolved to baseline severit
y or to CTCAE Gr ade 
≤1 except for adverse events ( AEs)that in the investigator’ judgment do not 
constitute a safet y risk for the participant .
11.Systemic anti -cancer therapy  with alectinib or ceritinib discontinued within a 
minimum of [ADDRESS_676089] dose of lorlatinib on the study  (unless clinically  
meaningful tumor flare per discretion of the investigator, in which discussion with the 
sponsor is warranted).
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 25Sex
12.Male or Female
Contraceptive use b y men or women should be consistent with local regulations 
regarding the methods of contraception for those participating in clinical studies.
     
a.Male participants:
Male participants are eligible to participate if they  agree to the following during the 
intervention period and for at least [ADDRESS_676090] dose of study  intervention: 
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual or homosexual intercourse as their preferred and 
usual lifesty le (abstinent on a long term and persistent basis) and agree to remain 
abstinent .
OR
Must agree to use contraception/barrier as detailed below :
Agree to use a male condom when engaging in any
 activity  that allows passage of 
ejaculate to another person .
Female partner of childbearing potential who is currentl y not pregnant must use 
an additional highl y effective contraceptive method with a failure rate of <1% per 
year as described in Appendix 4if having sexual intercourse with male 
participant .
b.Female participants:
A female participant is eligible to participate if she is not pregnant or breastfeeding, 
and at least one of the following conditions applies:
Is not a woman of childbearing potential (WOCBP) ( refer to Appendix 4) for 
definition .
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a 
failure rate of <1% per year), preferabl y with low user dependency, as described 
in Appendix 4during the intervention period and for at least 35daysafter the last 
dose of study  intervention and agrees not to donate eggs (ova, oocy tes) for the 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676091] dose of study  
intervention.
A WOCBP must have a negative highly  sensitive (at least 25 IU/Ml) pregnancy  
test (urine or serum as required by  [CONTACT_427]) immediately before the first 
dose of study  intervention.
If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy  test is required. I n such cases, the participant must be excluded from 
participation if the serum pregnancy  result is positive.
Additional requirements for pregnancy  testing during and after study  intervention are 
located in Section 8.2.6 .
The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  todecrease the risk for inclusion of a woman with an earl y 
undetected pregnancy .
Informed Consent
13. Capable of giving signed informed consent as described in Appendix 1 which 
includes compliance with the requirements and restrictions listed in the info rmed 
consent form (ICF) and in this protocol.
14.Willingness and ability  to comply  with the study  scheduled visits, treatment plans, 
laboratory  tests and other procedures.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the follow ing criteria apply :
Medical Conditions
1. Prior ALK TKI treatment or anti-cancer treatment other than first line alectinib or 
ceritinib. 
2. Spi[INVESTIGATOR_521276] y, and there is stabilization or recovery of neurological function for the 4 weeks 
prior to randomization.
3.Gastrointestinal abnormalities, including inability  to take oral medication; 
requirement for intravenous alimentation; prior surgical procedures affecting 
absorption including to tal gastric resection or lap band; active inflammatory  
gastrointestinal disease, chronic diarrhea, s ymptomatic diverticular disease; treatment 
for active peptic ulcer disease in the past 6 months; malabsorption sy ndromes.
4.Active and clinicall y significant 
bacterial, fungal, or viral infection including hepatitis 
B virus (HBV) or hepatitis C virus (HCV) (eg, in case of known hepatit is b surface 
antigen [ HBsAg ]or HCV antibody  positivity ), known human immunodeficiency  
virus (HIV), or acquired immunodeficiency  syndrome (AIDS) related illness.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 275.Clinically  significant vascular (both arterial and venous) and non- vascular cardiac 
conditions, (active or within 3 months prior to enrollment), which may include, but 
are not limited to: 
a.Arterial disease such as cerebral vascular accident/stroke (including 
Transient Ischemic Attack [ TIA]), my ocardial infarction, unstable angina;
b.Venous diseases such as cerebral venous throm bosis, sy mptomatic 
pulmonary  embolism;
c.Non vascular cardiac disease such as congestive heart failure ([LOCATION_001] 
Heart Association Classification Class ≥ II), second degree or third degree 
atrioventricular ( AV
)block (unless paced) or any  AV block with PR 
interval >220 msec; or ongoing cardiac d ysrhythmias of NCI  CTCAE Grade 
≥2, uncontrolled atrial fibrillation of any  grade, brady cardia defined as <50 
beats per minute ( bpm) (unless participant is otherwise healthy  such as long 
distance runners, etc.), machine read Electrocardiogram (ECG) with QTc 
>470 msec, or congenital long QT s yndrome.
6.Participant s presenting with abnormal Left Ventricular Ejection Fraction (LVEF) b y 
echocardiogram or Multi -Gated Acquisition Scan (MUGA) according to institutional 
lower limi ts.
7.Participant s with predisposing characteristics for acute pancreatitis according to 
investigator judgment (eg, uncontrolled hy pergl ycemia, h ypertrigl yceridemia, current 
gallstone disease, alcoholism [more than 4 drinks on any day  or 14 drinks per week 
where 1 drink is defined as the alcoholic beverage containing approximately  14grams 
of pure alcohol, eg, 12 fl oz/360 mL regular beer or 5 floz/150 mL of wine] in the 
last month.
8.History  or known presence of interstitial fibrosis, interstitial lung diseas e, 
pneumonitis, hy persensitivity  pneumonitis, interstitial pneumonia, obliterative 
bronchiolitis ,and pulmonary  fibrosis.
9.Other severe acute or chronic medical or ps ychiatric condition, including recent 
(within the past y ear) or active suicidal ideation or behavior, or laboratory  
abnormality  that may  increase the risk associated with study  participation or 
investigational product administration or may  interfere with the interpretation of 
study  results and, in the judgment of the investigator, would make the participant
inappropriate for entry  into this study .
10.Evidence of active malignancy  (other than current NSCL C, non -melanoma skin 
cancer, in situ cervical cancer, papi[INVESTIGATOR_521277], ductal carcinoma in situ 
(DCIS
)of the breast or localized and presu med cured prostate cancer) within the last 
3years prior to randomization.
Prior/Concomitant Therapy
11.Radiation therap y (except palliative to relieve bone pain) within 2 weeks of study  
entry .  Palliative radiation ( 10fractions) must have been completed at least 48 hours 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676092] 4 weeks prior to study  entry .
12.Prior irradiation to >25% of the bone marrow.
13.Concurrent use of an y of the following food or drugs (consult the sponsor if in doubt 
whether a food or a drug falls into any  of the above categories) within [ADDRESS_676093] dose of lorlatinib: 
a.Known strong CYP3A inducers (eg, carbamazepi[INVESTIGATOR_050], enzalutamide, mitotane, 
pheny toin, rifampin, St. John’s Wort). 
b.Known strong CYP3A inhibitors (eg, strong CYP3A4 inhibitors: grapefruit 
juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, 
pomelos], boceprevir, cobicist at, clarithromy cin, conivaptan, diltiazem, 
idelalisib, indinavir, itraconazole, ketoconazole, lopi[INVESTIGATOR_054], nefazodone, 
nelfinavir, paritaprevir and posaconazole, ritonavir, alone and with danoprevir 
or elvitegravir or indinavir or lopi[INVESTIGATOR_521278] o r ombitasvir or 
dasabuvir or saquinavir or tipranavir, telaprevir, troleandomy cin, and 
voriconazole, grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, 
Seville oranges, pomelos]). The topi[INVESTIGATOR_198288] (if 
applicable), such as 2% ketoconazole cream, is allowed.   Note that strong 
CYP3A inhibitors can be stopped up to one day  prior to first dose of lorlatinib 
on study .
c.Known CYP3A substrates with narrow therapeutic index, such as 
astemizole*, terfenadine*, cisapride*, pi[INVESTIGATOR_3924]
, quinidine, tacrolimus, 
cyclosporine, sirolimus, alfentanil, fentan yl (including transdermal patch) or 
ergot alkaloids (ergotamine, dihy droergotamine) (*withdrawn from United 
States [US] market).
d.Known permeability  glycoprotein ( P-gp)substrates with a n arrow therapeutic 
index (eg, digoxin). 
14.Major surgery  within 4 weeks prior to enrollment .  Minor surgical procedures (eg, 
port insertion) are not excluded, but sufficient time should have passed for adequate 
wound healing.
Other Exclusions
15.Known prior or suspected severe h ypersensitivity  to study  intervention s or any  
component in their formulations.
16.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  [CONTACT_17062], or 
[COMPANY_007] employ ees, including their family  members, directly  involved in the conduct of 
the study .
5.3.Lifestyle Considerations
1.See Appendix 4for mandatory  contraception information .
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 292.Refrain from consumption of grapefruit/grapefruit related citrus fruits (eg, Seville 
oranges pomelos) from [ADDRESS_676094] and use machines. Cautions 
should be exercised when driving or operating machines as participants may experience 
CNS effects.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  entered in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorit ies. Minimal information includes demography , 
screen failure details, eligibility  criteria, and any  serious adverse event (SAE).
Individuals who do not meet the criteria for participation in this study  (screen failure) may  
not be rescreened.  
6.STUDY INTE RVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
6.1.Study Intervention(s) Administered
ARM Name [CONTACT_297495] 100 mg QD
Intervention Name [CONTACT_521301] 25 mg
Dosage 100 mg QD
Route of Administration Oral
Sourcing Provided centrall y by [CONTACT_521293]. Each bottle 
will be labeled as required per country  requirement.
Current/Former Name(s) 
or Alias(es)PF-06463922/lorlatinib
6.2.Preparation/Handling/Storage/Accountability
1.The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676095] be stored in a secure, environmentally  controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with 
access limited to the investigator and authorized site staff.  At a minimum, daily  
minimum and maximum temperatures for all site storage locations must be 
documented and available upon request.  Data for nonworking day s must indicate the 
minimum and maximum temperature since previously  documented for all site storage 
locations upon return to business.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).  All study  
interventions will be accounted for using an investigational product accountability  
form/record. 
4.Further guidance and information for the fin al disposition of unused study  
interventions are provided in the investigation alproduct ( IP)manual.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_177264]. 
6.Study  interventions should be stored in their original containers and in accordance 
with the labels.
7.Site staff will instruct participants on the proper storage requirements for take -home 
study  intervention. 
8.Deviations from the storage requirements, including an y actions taken, must be 
docum ented and reported to [COMPANY_007] upon discovery.  The site should actively pursue 
options for returning the study  intervention to the storage conditions described in the 
labeling, as soon as possible.  Once an excursion is identified, the study  intervention 
must be quarantined and not used until [COMPANY_007] provides permission to use the study  
intervention.  I t will not be considered a protocol deviation if [COMPANY_007] approves the use 
of the study  intervention after the temperature excursion.  Use of the study  
intervent ion prior to [COMPANY_007] approval will be considered a protocol deviation.  Specific 
details regarding the definition of an excursion and information the site should report 
for each excursion will be provided to the site in the I P manual.
9.The sponsor or designee will provide guidance on the destruction of unused study  
intervention (eg, at the site).  If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destro yed in 
compliance with applicable en vironmental regulations, institutional policy , and any  
special instructions provided by  [CONTACT_4618], and all destruction must be adequately  
documented.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 316.3.Measures to Minimize Bias: Randomization and Blinding
Open -label using 
IVRS/I WRSThis is an open -label study ; however, the specific intervention to be 
taken b y a participant will be assigned using an interactive voice 
response s ystem(IVRS )/interactive web response sy stem (IWRS).  
The site will contact [CONTACT_21926]/I WRS prior to the start of study  
intervention administration for each participant.  The site will 
record the intervention assignment on the applicable case report 
form, if required.
6.4. Study Intervention Compliance
Participant compliance with study  intervention will be assessed at each visit. Compliance 
will be assessed b y counting returned tablets. Deviation(s) from the prescribed dosage 
regimen should be recorded in the electronic case report form ( eCRF ).
6.5.Concomi tant Therapy
All concomitant medications and non -drug supportive interventions should be recorded in the 
CRF until t he participant has completed 35 cycles of treatment (approxi mately  24months).  
After cy cle35 the data will be reported in the medical chart, but not collected in the CRF.
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or 
receives during the stud y must be record ed along with:
Reason for use
Dates of administration including start and end dates
The Medical Monitor should be contact[CONTACT_43205] y questions regarding concomitant or 
prior therap y.
6.5.1. Prohibited Concomitant Treatments
Concomitant treatment considered necessary  for the 
participant ’s wellbeing may  be given at 
discretion of the treating phy sician.
In vitro studies have demonstrated that CY3A and UGT1A4 are primaril y involved in the 
metabolism of lorlatinib, with additional minor contribution from cytochrome P450 
(CYP )2C8, CYP2C19, CYP3A5 and UGT1A3. Inhibition or induction of the above enzy mes 
may result in potential alteration of lorlatinib s ystemic exposure. 
To protect participant safety  the following cautions are provid ed:  
Lorlatinib metabolism may  be inhibited by  [CONTACT_297417]3A4/5 inhibitors leading to a 
potential increase in lorlatinib toxicities.  Concomitant administration of lorlatinib 
with strong CYP3A4/5 inhibitors (e.g. boceprevir, cobicistat, itraconazole, 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 32ketoc onazole, posaconazole, troleandom ycin, voriconazole, ritonavir, paritaprevir in 
combination with ritonavir and ombitasvir and/or dasabuvir, and ritonavir in 
combination with either elvitegravir, indinavir, lopi[INVESTIGATOR_521279]) may increase 
lorlatinib p lasma concentrations. Grapefruit products may  also increase lorlatinib 
plasma concentrations and should be avoided. An alternative concomitant medicinal 
product with less potential to inhibit CYP3A4/5 should be considered. If a strong 
CYP3A4/[ADDRESS_676096] had 
a dose reduction to 75 mg orally  once dail y due to adverse reactions and who initiate 
a strong CYP3A4/5 inhibitor, reduce lorlatinib dose to 50 mg orally  once daily .  If 
concurrent use of the strong CYP3A4/5 inhibitor is discontinued, lorlatinib should be 
resumed at the dose used prior to the initiation of the strong CYP3A4/5 inhibitor and 
after a washout period o f 3 to 5 half -lives of the strong CYP3A4/5 inhibitor. The 
participant should be closely  monitored for safet y and reduction of the lorlatinib dose 
if necessary .
The use of a strong CYP3A4/5 inducer (eg, carbamazepi[INVESTIGATOR_050], enzalutamide, mitotane, 
pheny toin, rifa mpin, St. John’s Wort) with lorlatinib is contraindicated and it should 
be avoided, if possible, as they  may  also reduce lorlatinib plasma concentration 
Furthermore, when lorlatinib was coadministered with rifampin ( Study  B7461011 ), 
increases in AST and AL T were noted.  Discontinue strong CYP3A inducers for 3 
plasma half -lives of the strong CYP3A inducer prior to initiating lorlatinib and until 
study  treatment discontinuation. In addition, use with moderate CYP3A inducers 
should be avoided due to the poten tial reduction in lorlatinib exposure.  
Lorlatinib inhibits CYP2C9 (in vitro), so concurrent use of drugs that are 
CYP2C9 substrates with narrow therapeutic indices, such as warfarin, phenytoin or 
celecoxib, may  have increased effect.  Concomitant CYP2C9 substrates should be 
used with caution, as the net clinical effect of lorlatinib on CYP2C9 is currently  being 
investigated.
Lorlatinib induces CYP2B6 (in vitro) so concurrent use of drugs that are 
CYP2B6 substrates, such as bupropi[INVESTIGATOR_408003], may  have less effect. 
Concomitant CYP2B6 substrates (e.g. bupropi[INVESTIGATOR_2394], efavirenz) should be used with 
caution, as the net clinical effect of lorlatinib on CYP2B6 is currently  being 
investigated. 
In vitro studies indicated that lorlatinib is a time -dependent inhibi tor as well as an 
inducer of CYP3A4/5 and it activates the human pregnane-X- receptor (PXR), with 
the net effect in vivo being induction. Thus, concurrent administration of lorlatinib 
with CYP3A4/5 substrates with narrow therapeutic indices, including but n ot limited 
to alfentanil, ciclosporin dihy droergotamine, ergotamine, fentan yl, hormonal 
contraceptives, pi[INVESTIGATOR_3924], quinidine, sirolimus and tacrolimus, should be avoided 
since the concentration of these medicinal products may  be reduced by  [CONTACT_521294].  
Howe ver, if it is absolutely  necessary  to use, sponsor approval is required and the 
dose of the CYP3A4/5 substrate may  need to be increased.  The n arrow therapeutic 
index ( NTI) CYP3A4/[ADDRESS_676097] 14 days of 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 33continuous lorlatinib dosing.  If there is a change in the lorlatinib dosing regimen 
such as a dosing interruption or dose reduction, the administration of the NTI 
CYP3A4/[ADDRESS_676098] 14 day s of re sumed lorlatinib dosing .
In vitro studies indicated that lorlatinib may  inhibit P-gp (sy stemicall y and at the 
gastrointestinal tract), breast cancer resistance protein ( BCRP ) (gastrointestinal [GI]
tract), OATP1B1, OATP1B3, OCT1, MATE1 and OAT3 at clinica lly relevant 
concentrations. The concurrent use of drugs which are P -gp substrates with narrow 
therapeutic index, such as digoxin is not permitted at study  entry .  The use of these 
drugs during the study  is not recommended and alternate medications should be 
considered.  If absolutel y necessary  to use during the study , it should be initiated 
following sponsor approval, and be used then with caution.  The net clinical effect of 
lorlatinib on P -gp is currently  being investigated.
In vitro studies indicated th at lorlatinib may  have the potential to inhibit UGT1A1 .
Other Anti -Tumor or Experimental Drugs
No additional sy stemic anti- tumor therap y will be permitted while participants are receiving 
a study  therapy .  Additionally , the concurrent use of select herbal supplements (St John’s 
wort, ginseng, and goldenseal)15is not permitted.
Hematopoietic Growth Factors
Primary  prophy lactic use of granulocy te-colony stimulating factors is not permitted during 
the first cy cle but they  may  be used to treat treatment emergent neutropenia as per standard 
of care. 
If approved and available for use per country  regulations, ery thropoietin may  be used at the 
investigator’s discretion for the supportive treatment of anemia.
6.5.2. Permitted Concomitant Trea tments
Bisphosphate Therap y
Bisphosphonate therap y for metastatic bone disease is permitted.  Bisphosphonate therap y 
should be given as per local medical practice.
Lipid -Lowering Therap y
Since statins can be metabolized or inhibited by  [CONTACT_521295]450 pathways as lorlatinib 
(Table 1), pi[INVESTIGATOR_521280]
t involved with the CYP450 enzy me 
systems. However, no clinical drug -drug interactions have been formall y studied with 
lorlatinib and careful monitoring is advised.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 34Table 1. Pharmacokinetic Properties of Statins
Pi[INVESTIGATOR_521281], 
AltocorLescol
Metabolism† ++ + + +++ +++ +++ +++
Metabolizing 
CYP enzymes 
(of lactone or 
acid form)(2C9) (3A4) 2C9 (2C19) 3A4 (2C8) 3A4 2C8 3A4 2C8 2C9
Inhibitor of 
CYP3A4‡- - + + + + +
Inhibitor of 
CYP2C9‡- - (+) - - - +
Triglyceride 
lowering effect22%-31%** 11%-14%* 17%* 14%-19%* 10%-14%* 13%* 5%***
Adapted from Neuvonen et al, 200616.
Parentheses indicate minor significance.
†Three plus signs indicate extensively metabolized, and 1 plus sign indicates limited metabolism, eliminated mainly unchanged .
‡A plus sign indicates yes, and a minus sign indicates no.
* Baseline TG 100 -200 mg/dL; Effect of Statins vs Placebo on Triglyceride Levels in 10 Primary and Secondary Placebo -Controlled Outcome Trials table 
in Miller 200917.
** Baseline TG 150 mg/dL; Kajinami et al, 200318.
*** Schaefer et al, 200419.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676099] involvement with the CYP450 enzy me sy stems ( Table 2).  
No clinical drug -drug interactions have been formally  conducted with lorlatinib and agents 
listed in Table 2so 
careful monitoring is advised. 
Table 2. Pharmacokinetic properties of Lipid Lowering Agents
Fibric Acids Fish Oils
Generic Name [CONTACT_521302]-3 fatty acids
Tradename [CONTACT_521303]®, Nicor®aLopid®bTriCor®cLovaza®d
Dose 100–2000 mg QD 600 mg BID 200 mg QD 4 gm QD/ 2 gm 
BID
Metabolism‡ - - - -
Metabolizing CYP
enzymes (of 
lactone or acid 
form) ‡- - - -
Inhibitor of 
CYP3A4 ‡- - - -
Inhibitor of 
CYP2C9 ‡- +++ ++ -
Inhibitor of 
CYP2C19 ‡- ++ + -
Inhibitor of 
CYP1A2 ‡- + - -
Triglyceride 
lowering effect
(TG 150 mg/dL)20%-50%* 20%-50%* 36%-55%e45%
Drug Interactions Caution should be 
used when 
prescribing niacin 
with statinsConcomitant 
administration with 
statins is 
contraindicatedMay increase 
exposure to 
pravastatin and its 
metabolite (13% -
26%) w hen used 
concomitantly-
‡A plus sign indicates yes, and a minus sign indicates no.
* NCEP -ATP III, 2001.
BID = tw ice daily; QD = once daily.
a.PI, 4/2015
b.PI, 11/2014
c.PI, 12/2014
d.PI, 05/2014
e.Primary hypertriglyceridemia –severe hypertriglyceridemia (Baseline TG levels 500 to 1500 mg/dL)
Radiotherap y
Palliative radiotherap y on study  is permitted for the treatment of painful bony  lesions 
providing the lesions were known at the time of study  entry  and the investigator clearl y 
indicates that the need for palliative radiotherap y is not indicative of diseas e progression.  In 
view of the current lack of data about the interaction of lorlatinib with radiotherap y, lorlatinib
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676100] 2 days prior to surgery .  Postoperativel y, the de cision to reinitiate 
lorlatinib treatment should be based on a clinical assessment of satisfactory  wound healing 
and recovery  from surgery .
6.6. Dose Modification
Dosing interruption or dose reduction may  be required based on individual safet y and 
tolerability .
Lorlatinib dose reduction levels are summarized below:
First dose reduction: 75 mg taken orall y once daily
Second dose reductio n: 50 mg taken orally once daily
Lorlatinib should be permanently discontinued if the participant is unable to tolerate the 
50mg dose taken orall y once dail y.
Dose modification recommendations for toxicities and for participants who develop 
atrioventricular (AV) block are provided in Table 3
Table 3. Recommended Lorlatinib Dose Modifications for Adverse Reactions
Adverse ReactionaLorlatinib Dosing
Hypercholesterolemia and Hypertriglyceridemia
Mild hypercholesterolemia (cholesterol betw een 
ULN and 300 mg/dL or betw een ULN and 7.75 
mmol/L)
OR
Moderate hypercholesterolemia (cholesterol betw een 
301 and 400 mg/dL or betw een 7.76 and 10.34 
mmol/L)
OR
Mild hypertriglyceridemia (triglycerides between 
150 and 300 mg/dL or 1.71 and 3.42 mmol/L)
ORIntroduce or modify lipid -lowering therapybin
accordance w ith respective prescribing information;
continue lorlatinib at same dose.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 37Table 3. Recommended Lorlatinib Dose Modifications for Adverse Reactions
Adverse ReactionaLorlatinib Dosing
Moderate hypertriglyceridemia (triglycerides 
betw een 301 and 500 mg/dL
or 3.43 and 5.7 mmol/L)
Severe hypercholesterolemia (cholesterol betw een 
401 and 500 mg/dL or betw een 10.35 and 12.92 
mmol/L)
OR
Severe hypertriglyceridemia (tri glycerides between 
501 and 1,000 mg/dL or 5.71 and 11.4 mmol/L)Introduce the use of lipid -lowering therapyb; if 
currently on lipid-lowering therapy, increase the 
dose of this therapybin accordance with respective 
prescribing information; or change to a new lipid -
lowering therapyb. Continue lorlatinib at the same 
dose w ithout interruption.
Life-threatening hypercholesterolemia (cholesterol 
over 500 mg/d L or over 12.92 mmol/L)
OR
Life-threatening hypertriglyceridemia (triglycerides 
over 1,000 mg/dL or over 11.4 mmol/L)Introduce the use of lipid -lowering therapybor 
increase the dose of this therapybin accordance with 
respective prescribing information or change to a 
new lipid -lowering therapyb. Withhold lorlatinib 
until recovery  of hypercholesterolemia and/or 
hypertriglyceridemia to moderate or mild severity 
grade.
Re-challenge at same lorlatinib dose while 
maximizing lipid -lowering therapybin accordance 
with respective prescribing information.
If severe hypercholesterolemia and/or 
hypertriglyceridemia recur despi[INVESTIGATOR_521282]-lowering therapybin accordance w ith 
respective prescribing information, reduce lorlatinib 
by 1 dose level.
Central Nervous System Effects (changes in cognition, mood, or speech)
Grade 2: Moderate
OR
Grade 3: SevereWithhold dose until toxicity is less than or equal to 
Grade 1. Then resume lorlatinib at 1 reduced dose 
level.
Grade 4: Life -threatening/urgent intervention 
indicatedPerm anently discontinue lorlatinib
Lipase/Amylase Increase
Grade 3: Severe 
OR
Grade 4: Life -threatening/urgent intervention 
indicatedWithhold lorlatinib until lipase or amylase returns to 
baseline. Then resume lorlatinib at 1 reduced dose 
level.
Interstitial Lung Disease (ILD)/Pneumonitis
Grade 1: Mild 
OR
Grade 2: ModerateWithhold lorlatinib until symptoms have returned to 
baseline and consider initiating corticosteroids.
Resume lorlatinib at 1 reduced dose level.  
Perm anently discontinue lorlatinib if 
ILD/pneumonitis recurs or fails t o recover after 6 
weeks of lorlatinib hold and steroid treatment.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 38Table 3. Recommended Lorlatinib Dose Modifications for Adverse Reactions
Adverse ReactionaLorlatinib Dosing
Grade 3: Severe 
OR
Grade 4: Life -threatening/urgent intervention 
indicatedPerm anently discontinue lorlatinib
PR interval prolongation/Atrioventricular (AV) block
First Degree AV Block
AsymptomaticContinue lorlatinib at the same dose w ithout 
interruption. Consider effects of concomitant 
medicinal products and assess and correct electrolyte 
imbalance that may prolong PR interval. Monitor 
ECG/symptoms potentially related to AV block 
closely.
First Degree AV Block
SymptomaticWithhold lorlatinib . Consider effects of concomitant 
medicinal products and assess and correct electrolyte 
imbalance that may prolong PR interval. Monitor 
ECG/symptoms potentially related to AV block 
closely. If symptoms resolve, resume lorlatinib at 
1reduced dose level.
Second Degree AV Block
AsymptomaticWithhold lorlatinib. Consider effects of concomitant 
medicinal products and assess and correct electrolyte 
imbalance that may prolong PR interval. Monitor 
ECG/symptoms potentially related to AV block 
closely. If subsequen t ECG does not show  second 
degree AV block, resume lorlatinib at [ADDRESS_676101] electrolyte 
imbalance that may prolong PR interval. Refer for 
cardiac observation and monitoring. Pacemaker 
placement may be indicated for severe symptoms 
associated with AV block. If AV block does not 
resolve, placement of a permanent pacemaker may 
be considered.
If pacemaker placed, resume lorlatinib at full dose. If 
no pacemaker placed, resume lorlatinib at 1 reduced 
dose level only when symptoms resolve, and PR 
interval is less than 200 msec.
Other Adverse Reactions
Grade 1: Mild 
ORConsider no dose modification or reduce by 1 dose 
level, as clinically indicated.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 39Table 3. Recommended Lorlatinib Dose Modifications for Adverse Reactions
Adverse ReactionaLorlatinib Dosing
Grade 2: Moderate
Greater than or equal to Grade 3: Severe Withhold lorlatinib until symptoms resolve to less 
than or equal to Grade 2 or baseline. Then resume 
lorlatinib at 1 reduced dose level.
Abbreviations: AV=Atrioventricular; CTCAE=Common Terminology Criteria for Adverse Events; 
ECG=electrocardiogram;
HMG CoA=3 -hydroxy -3-methylglutaryl coenzyme A; NCI=National Cancer Institute; ULN=upper limit of
norm al.
a.Grade categories are based on NCI CTCAE classifications.
b.Lipid low ering therapy may include: HMG CoA reductase inhibitor, nicotinic acid, fibric acid 
derivatives, or ethyl esters of omega [ADDRESS_676102] y with lorlatinib will be 
considered based on the local availability  of the treatment and local country  laws/regulation.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUA TION/WITHDRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a patient to permanentl y discontinue study 
intervention. If stud y intervention is permanentl y discontinued, the participant will remain in 
the study  to complete all remaining scheduled assessments.
See Table [ADDRESS_676103] of the participant.
If a clinical ly significant finding is identified (including, but not limited to changes from 
baseline in QT interval corrected using Fridericia’s formula (QTcF )after enrollment 
(Appendix 7), the investigator or qualified designee will determine if the participant can 
continue in the study  and if any  change in participant management is needed. This review of 
the ECG printed at the time of collection must be documented. An y new clinically  relevant 
finding should be reported as an AE.
If a clinically  significant finding is identified after enrollment, the investigator or qualified 
designee will determine if the participant can continue in the study  and if any  change in 
participant management is needed.
See the schedule of activities ( SoA) for data to be collected at the time of intervention 
discontinuation and follow- up and for an y further evaluations that need to be completed.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676104] y.
In the event of a treatment interruption for reasons other than treatment related toxicity  (eg, 
elective surgery ) lasting >[ADDRESS_676105] dose 
should discontinue lorlatinib treatment. 
If a treatment interruption continues bey ond Day 21 of the current cy cle, then the day  when 
treatment is restarted will be counted as Day 1 of the next cy cle.  Every  effort should be 
made to maintain the tumor assessments scheduling as every  6 weeks (±1 week) or per local 
practice versus the date of Cy cle1 Day 1.
7.2.Participant Discontinuation/Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit 
should be conducted, as shown in the SoA. See SoA for data to be collected at the 
time of study  discontinuation and follow -up and for an y further evaluations that need 
to be com pleted.
The early discontinuation visit applies only  to participants who are enrolled and then 
are prematurel y withdrawn from the stud y.  Participants should be questioned 
regarding their reason for withdrawal.  The participant will be permanentl y 
discontinued both from the study  intervention and from the study  at that time.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site study  
records and notify  the sponsor accordingly .
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 41If the participant withdraws from the study and also withdraws consent (see below) 
for disclosure of future information, no further evaluations should be performed and 
no additional data should be collected.  The sponsor may retain and continue to use 
any data collected before such withdrawal of consent.
When a participant withdraws from the stud y because of an SAE, the SAE must be 
recorded on the case report form ( CRF )and reported on the clinical trial serious 
adverse e vent ( CT SAE )Report.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
Reasons for withdrawal of study  treatment may  include:
Object ive disease progression; 
Global deterioration of health status requiring discontinuation;
Unacceptable toxicity ;
Pregnancy ;
Significant protocol violation;
Lost to follow -up;
Participant refused further treatment;
Study  terminated by  [CONTACT_3211];
Death.
7.3.Lost to Follow up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
Reasons for withdrawal from study  follow -up may include:
Completed study  follo w-up;
Study  terminated by  [CONTACT_3211];
Lost to follow -up;
Refused further follow -up;
Death.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676106] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_521296]/or 
should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole are handled as part of Appendix 1.
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a 
signed and dated ICFbefore performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study
 conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligi bility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable.
Every  effort should be made to ensure that protocol -required t ests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  
be circumstances outside the control of the investigator that may  make it unfeasible to 
perform the test.  In these cases, the investigator must ta ke all steps necessary to 
ensure the safet y and well -being of the participant.  When a protocol -required test 
cannot be performed, the investigator will document the reason for the missed test 
and an y corrective and preventive actions that he or she has ta ken to ensure that 
required processes are adhered to as soon as possible.  The study  team must be 
informed of these incidents in a timely  manner.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 43Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count) and obtained before signing of the ICF may be utilized for screening or 
baseline purposes provided the procedures met the protocol -specified criteria and 
were performed within the time frame defined in the SoA.
8.1.Efficacy Assessments
8.1.1. Tumor Assessments
Tumor assessment s will include all known or suspected disease sites.  Computed tomograph y 
(CT)or MRI scans of Chest Abdomen Pelvis (CAP) and MRI  of the brain will be performed 
at screening.  Gadolinium contrast enhanced MRI must be used for assessment of CNS 
lesions with contingent slices of 1 mm for lesions 5 mm – 10 mm in size, 5 mm for lesions 
greater than 10 mm.  Bone scans (or bone MRI if preferred b y investigator) will be 
performed at baseline for all participants and repeated every  12weeks on study  only if 
evidenc e of bone metastases is observed at baseline (however, if a participant has bone 
involvement, assessment of those sites via appropriate modality  is required every  6 weeks ±[ADDRESS_676107]).  For all tu mor 
assessments, the method of assessment that was used at baseline should be the same method 
used throughout the study.  CT and MRI scans to be done at every  6weeks ±1 week up to 
approximately  24months (cy cle35) and then as per local clinical practice. Tumor assessment 
should be repeated at the end of treatment if more than [ADDRESS_676108] 
evaluation. Tumor assessment should not be repeated at the end of treatment if progression 
occurs when the participant has shifted to the local cli nical practice. Moreover, radiological 
tumor assessments will be conducted whenever disease progression is suspected (eg, 
symptomatic deterioration).
Assessment of response will be made using RECIST version 1.1 ( Appendix 5).  
Confirmation of response will be required at least 4 weeks after initial response is observed.
All participants’ files and radiologic images must be available for source verification and for 
peer/independent central radiology  review as determ ined by  [CONTACT_456]. Instructions for 
submission of these images will be provided in the Study  Reference Manual.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA and in the lorlatinib 
product information.  Unsch eduled clinical laboratory  measurements may  be obtained at an y 
time during the stud y to assess an y perceived safety  concerns.
8.2.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
Cardiovascular, Respi[INVESTIGATOR_696] , Gastrointestinal and Neurological s ystems and ECOG 
status. Weight will also be measured and recorded.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 448.2.2. Electrocardiograms
Triplicate 12 -lead ( with a 10 -secon d rhythm strip).  ECG will be obtained as outlined 
in the SoA (see Section 1.3) using an ECG machine that automaticall y calculates the 
heart rate and measures PR, QRS, QT, and QTc intervals. Refer to Section 7for QTc 
withdrawal criteria and any  additional QTc readings that may  be necessary .  Refer to 
Section 6.6 for PR interval prolongation/AV block.
At each time point at which triplicate ECG are required, 3 individual ECG tracings 
should be obtained as closely  as possible in succession, but no more than 2 minutes 
apart. The full set of triplicates should be completed in less than 4 minutes.
If at an y of these time points the mean PR interval is prolonged ( ≥200 msec) or QTc 
is prolonged ( ≥501 msec), the ECGs should be re -evaluated b y a qualified pe rson at 
the institution for confirmation.
PR interval prolongation and AV block have been reported in participant s receiving 
lorlatinib.  ECG will be monitored prior to initiating lorlatinib and monthly thereafter, 
particularl y in participants with predisp osing conditions to the occurrence of 
clinically  significant cardiac events. Dose modification may  be required for those 
participants who develop AV block (See Section 6.6).
ECG values of potential concern are listed in Appendix 7.
8.2.3.
Echocardiograms/Multigated (MUGA) Acquisition Scan
Echocardiogram or MUGA will be performed at screeni ng. Additional assessments may  be 
performed as clinicall y indicated and according to lorlatinib product information .  LVEF 
decrease has been reported in participant s receiving lorlatinib. In participants who develop 
relevant cardiac signs/s ymptoms during t reatment, cardiac monitoring, including LVEF 
assessment, should be considered.  The same method should be used throughout the study .
For [LOCATION_009] and German y, a transthoracic echocardiogram (TTE) will be performed every  
6months (± 2 weeks) during treatment, and onl y at the end of treatment visit if the previous 
assessment was > 1 month. Pulmonary  arterial pressure (PAP) will be assessed.
8.2.4. ECOG Performance Status
Refer to Appendix 9for ECOG Performance Status Criteria.
8.2.5. Clinical Safety Laboratory Assessments
See Appendix 2for the list of clinical laboratory  tests to be performed and to the SoA 
for the timing and frequency .
The use of lorlatinib has been associated with increases in serum c holesterol and 
triglycerides.  Serum cholesterol and triglycerides should be monitored before 
initiation of lorlatinib; 2, 4 and 8 weeks after initiating lorlatinib; and regularly  
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 45thereafter. Initiate or increase the dose of lipid-lowering medicinal produc ts, if 
indicated (see Section 6.6).
The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
CRF. The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged by  [CONTACT_55885]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 28days after t he last dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer 
considered clinically  significant by  [CONTACT_10982].
If such values do not return to normal/baseline within a period o f time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA.
If laboratory  values from non
-protocol specified laboratory  assessments 
performed at the institution’s local laboratory  require a change in participant 
management or are considered clinically  significant by  [CONTACT_093], then the 
SAE or AE or dose modification must be recorded in the CRF.
8.2.6. Pregnancy Testing 
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL.  Pregnancy  tests will be performed in women of childbearing potential 
(WOCBP) at the times listed in the SoA ( Section 1.3 ).  Followin g a negative pregnancy  test 
result at screening, appropriate contraception must be commenced and a second negative 
pregnancy  test result will be required at the baseline visit prior to the participant’s receiving 
the study  intervention.  Pregnancy  tests wi ll also be done whenever 1 menstrual cy cle is 
missed during the active treatment period (or when potential pr egnancy  is otherwise 
suspected), 
at the end of the study , and at follow -up.  Pregnancy  tests may  also be repeated if 
requested b y institutional rev iew boards (IRBs)/ethics committees (ECs) or if required by  
[CONTACT_427].  If a urine test cannot be confirmed as negative (eg, an ambiguous result), a 
serum pregnancy  test is required.  In such cases, the participant must be excluded if the 
serum pre gnancy  result is positive.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE or SAE can be found in Appendix 3.
AE will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant's legall y autho rized representative).
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 46The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE, or that caused the participant to discontinue 
the study  intervention (see Section 7).
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain the adequate 
supporting documentation, including laboratory  tests and cardiac assessments, to elaborate 
the AEs and SAEs occurring during the course of the s tudy and any  subsequent safet y 
follow -up. in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving investigational product), through and including 
a minimum of 28calendar day s after the last administration of the investigational product.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study  and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
Medical occurrences that begin before the start of study  intervention but after obt aining 
informed consent will be recorded on the Medical History /Current Medical Conditions 
section of the case report form (CRF) not the AE section.
Follow up by  [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
Investigators are not obligated to activel y seek AE or SAE after conclusion of the study  
participation . However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the s ponsor .
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety 
All SAEs occurring in a participant during the active collection period are reported to [COMPANY_007] 
Safety  on the clinical trial SAE Report Form immediatel y and under no circumstance should 
this exceed [ADDRESS_676109] still be r eported to [COMPANY_007] Safety  irrespective of any  intervening 
treatment.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 47SAEs occurring in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .
[IP_ADDRESS]. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non-serious AEs and SAEs are recorded on the 
CRF.
If a participant begins a new anticancer therap y, the recording period for non -serious AEs 
ends at the time the new treatment is started; however, SAEs must continue to be recorded on 
the CRF during the above
-indicated activ e collection period.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proact ively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medi cations 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4. Regulatory Re porting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a SAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and the 
safet y of a stud y intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will comply  with country -specific regula tory requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and investigators.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 48Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or other 
specific safet y information (eg, summary or listin g of SAEs) from the sponsor will 
review and then file it along with the SmPC and will notify  the IRB/IEC, if 
appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
Details of all pregnancies in female participants and female partners of ma le 
participants will be collected after the start of study intervention and until [ADDRESS_676110] dose.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours 
of learning of the pregnancy  and should follow the procedures outlined in Appendix 4
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are cons idered SAEs.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’ s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure 
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a participant enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676111] SAE Report 
Form to [COMPANY_007] Safety Within 24 
Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SA E
Medication errors include:
Medication errors involving participant exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether o r not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and non -serious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_676112] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of lorlatinib greater than 100 mg within a 24 -hour time period wi ll 
be considered an overdose.
Sponsor does not recommend specific treatment for an overdose.  There is no antidote for 
lorlatinib.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_27465] .
2.Closely  monitor the participant for an y AE/SAE and given the dose dependent effect 
on PR interval, ECG monitoring is recommended.  
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 503.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Safety  only when associated with a SAE .
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_55887].
8.5.Pharmacokinetics
Pharmacokinetic samples are not being collected in this study .
8.6.Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .
8.7.Genetics
8.7.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.7.2. Banked Biospecimens for Genetics
Banked biospecimen samples are not being collected in this study .
8.8.Biomarkers
Biomarkers are not evaluated in this study .
8.9.Health Economics
Not applicable to this study .
9.STATISTICAL CONSIDERATIONS
Detailed methodology  for summary  and statistical analyses of the data collected in this study  
is outlined here and further detailed in a statistical anal ysis plan (SAP), which will be 
maintained by  [CONTACT_456].  The SAP may  modify  what is outlined in the protocol where 
appropriate; however, any  major mo difications of the primary  endpoint definitions or their 
analyses will also be reflected in a protocol amendment.
9.1.Estimands and Statistical Hypotheses
The primary objective of the study  is to evaluate overall and intracranial anti -tumor activity  
of singl e-agent lorlatinib in participants with advanced ALK- positive NSCLC whose disease 
has progressed on alectinib or ceritinib as the first ALK ty rosine kinase inhibitor (TKI) 
therap y, by [CONTACT_30432] a superiority  of lorlatinib versus historical control ,of which the ORR is 
≤30%.  The study  will be considered to show this superiority  if the lower limit of the 95% 
confidence interval around the estimated ORR excludes 30%.
Tumor responses and progressions will be evaluated as per RECIST V 1.1.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676113] to discontinuation from treatment. 
Point estimates of ORR (defined as the percentage of participants with confirmed complete 
response [ CR
]or confirmed partial response [ PR]) and confidence intervals (following the 
methodology  outlined in Section 9.4.1 ) will be calculated.  Both CR and PR must be 
confirmed b y repeat assessments performed no less than [ADDRESS_676114] is based on INV.
The estimand for intracranial objective response (IC-OR)by [CONTACT_89169]/INV is the intra cranial 
treatment effect of lorlatinib from time of first dose until intra cranial progression is met or 
subsequent anti -cancer therap y is administered for all participants who receive at least one 
dose of lorlatinib without regard to discontinuation from treatment. 
Point estimates of intracranial objective response rate ( IC-ORR )by [CONTACT_89169]/INV (defined as the 
percentage of participants with confirmed CR or confirmed PR in brain) and confidence 
intervals (following the methodology  outlined in Section 9.4.1) will be calculated.  Both CR 
and PR in brain must be confirmed b y repeat assessments performed no less than [ADDRESS_676115] met.
The estimand for TTR by [CONTACT_89169]/I NVis the treatment effect from the time of first dose to the
first date of OR(CR or PR) that is subsequently  conf irmed for responders to lorlatinib.  TTR 
is defined as the time from the date of first dose to the date of first documentation of 
confirmed OR (CR or PR).
The estimand for DOR by  [CONTACT_89169]
/INVis the treatment effect from the first date of OR that is 
subsequently  confirmed for responders to lorlatinib until progression or death, without regard 
to discontinuation from treatment unless new anti
-cancer therap y is initiated or extende d gap 
in tumor assessment is present prior to progression or death .  DOR is defined as the time 
from first documentation of confirmed OR (CR or PR) to the date of first documentation of 
progression of disease (PD) or death due to an y cause, whichever occur s first.
The estimand for IC -DOR by  [CONTACT_89169]/INV is the treatment effect from the first date of OR 
that 
is subsequently  confirmed in brain for responders to lorlatinib, until intra cranial progression 
or death, without regard to discontinuation from treatment u nless new anti -cancer therap y is 
initiated or extended gap in tumor assessment is present prior to intra cranial progression or 
death.  IC -DOR is defined as the time from first documentation of confirmed OR in brain 
(CR or PR) to the date of first documentation of PD in brain or death due to any  cause, 
whichever occurs first.
The estimand for TTP by I CR/INV is the treatment effect from the time of first dose for all 
participants who receive at least one dose of lorlatinib until progression, without regard t o 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676116] documented PD due to an y cause.
The estimand for PFS by [CONTACT_89169]/INV is the treatment effect from the time of first dose for all 
participants who receive at least one dose of lorlatinib until progression or death due to an y 
cause, without regard to discontinuation from treatment unless new anticancer therap yis 
initiated or an extended gap in tumor assessment is present prior to progression or death. PFS 
is defined as the time from date of first dose to the date of the first documented disease 
progression or death due to any  cause, whichever occurs first.
9.2.Sample Size Determination
The primary  endpoint is Objective tumor response assessed by  [CONTACT_44993] 1.[ADDRESS_676117] 95% CI  (using an 
exact Clopper -Pearson CI).
According to literature, platinum -based doublet chemotherap y in patients with AL K + 
NSCL C refractory  to second generation TKIs has an objective response rate of 
approximately 30%.20Setting as target for lorlatinib a response rate of about 43% (as 
observed in cohort EXP -3B of phase 2 portion of study  B7461001), a sample size of 
60participants would result in a n exact two-sided 95% CI  of the ORR with lowe r limit of the 
CI greater than 30%.  In order to compensate for a potential 15% drop out rate (participants 
with death prior to first post -baseline assessment, inadequate baseline assessment, new anti -
cancer therap
y started prior to first post -baseline assessment, post- baseline disease 
assessments missing ), the overall sample size for the study  is set to [ADDRESS_676118] met its primary  endpoint if the lower limit of the 95% 
confidence interval around the estimated ORR excludes 30%.
9.3.Populations for Analyses
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICF
Intent to T reat (I TT)/Safety All enrolled participants who take at least 1 dose of lorlatinib
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 53Population Description
Per Protocol Population:
Participants with CNS 
metastases based on 
Independent Central ReviewSubset of the ITT analysis set including only participants with CNS 
metastases at study entry (i.e. with Lesions having Disease Site=Brain) 
according to Independent Central Review
Per Protocol Population:
Participants with CNS 
metastases based on 
Investigator AssessmentSubset of the ITT analysis set including only participants with CNS 
metastases at study entry (i.e. with Lesions having Disease Site=Brain) 
according to Investigator Assessment
9.4. Statistical Analyses
Thestatistical anal ysis plan will be developed and finalized before database lock and will 
describe the participant populations t o be included in the anal yses, and procedures for 
accounting for missing, unused, and spurious data. This section is a summary of the planned 
statistical analy ses of the primary  and secondary  endpoints.
9.4.1. Efficacy Analyses
Endpoint Statistical Analysis Met hods
Primary Confirmed OR by [CONTACT_89169] 
Population: ITT
Using an exact method based on binomial distributions, estimate the 
confirmed ORR b y ICR and corresponding two -sided 95% CI, 
based on OR from the time of first dose until progression is met or 
subsequent anti -cancer therap y is administered without regard to 
discontinuation from treatment. Participants with death prior to first 
post-baseline a ssessment, inadequate baseline assessment, new anti-
cancer therapy started prior to first post -baseline assessment, and all 
post-baseline disease assessments missing will be considered as 
non-responders.  
Secondary Confirmed OR by [CONTACT_521292] 
Population: ITT
Use the same statistical analy sis methods as for the primary  
endpoint except that the treatment effect is based on INV.
Confirmed IC -OR by [CONTACT_89169]
Population: Per protocol population of participants with CNS 
metastases based on Independent Central Review
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676119] method based on binomial distributions, estimate the 
confirmed IC -ORR by  [CONTACT_521297] -sided 95% CI, 
based on intra cranial OR from the time of first dose until intra 
cranial progression is met or subsequent anti- cancer therapy  is 
administered without regard to discontinuation from treatment. 
Participants with death prior to first post-baseline assessment, 
inadequate baseline assessment, new anti -cancer therap y started 
prior to first post -baseline assessment, and all post -baseline dise ase 
assessments missing will be considered as non -responders.  
TTR by [CONTACT_89169]/INV and IC- TTR by [CONTACT_89169]/INV
TTR is defined as the time from first dose to first documentation of 
objective tumor response (CR or PR) that is subsequently  
confirmed .  For patients whos e OR proceeds from PR to CR, the 
onset of PR is taken as the onset of response.  TTR will only  be 
calculated for the subgroup of patients with a confirmed objective 
tumor response.   
All the anal yses will be repeated also for Time toIntracranial 
Response (IC-TTR ) considering patients with intracranial response 
(i.e. Best Overall I ntracranial Response as confirmed Complete 
Response (CR) or confirmed Partial Response (PR) considering 
only the Lesions having Disease Site=Brain).   
TTR and I C-TTR will be summarized based on both I CR and 
derived investigator assessments using descriptive statistics.
DOR by [CONTACT_89169] /INV
Using the Kaplan -Meier method, estimate its associated statistics on 
DOR (including the median DOR with two -sided 95% CI) for 
responders to lorlatinib, without regard to discontinuation from 
treatment unless new anti -cancer therapy is initiated or extended gap 
in tumor assessment is present prior to progression or death . DOR is 
defined as the time from first documentation of OR (CR or PR) that 
is subsequently  confirmed to the date of first documentation of PD 
or death due to an y cause, whichever occurs first. 
This analy sis is based on responders onl y from the ITT population. 
Participants with an event more than 12 weeks ([ADDRESS_676120] the 
first42 weeks) after the last adequate tumor assessment will be 
censored on the date of the last adequate tumor assessment prior to 
the gap that documented no progression. If a new anti- cancer 
therap y starts prior to an event, the participant will be cens ored on 
the date of the last adequate tum or assessment that documented no 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 55Endpoint Statistical Analysis Met hods
progression prior to start of the new anti- cancer therap y. The CI for 
the median DOR will be calculated according to Brookmey er and 
Crowley  method.
IC-DOR by [CONTACT_89169]/INV
Using the Kapla n-Meier method, estimate its associated statistics on 
IC-DOR (including the median I C
-DOR with two- sided 95% CI) for 
intra cranial responders to lorlatinib, without regard to 
discontinuation from treatment unless new anti- cancer therap y is 
initiated or ext ended gap in IC tumor assessment is present pr ior to 
progression or death. IC -DOR is defined as the time from first 
documentation of IC -OR (CR or PR) 
that is subsequently  confirmed 
to the date of first documentation of intra cranial PD or death due to 
any cause, whichever occurs first. 
This analy sis is based on intra cranial responders only  from 
Participants with CNS metastases populations. Participants with an 
event more than 12 weeks ([ADDRESS_676121] 42weeks) after 
the last adequate tumor assessment will be censored on the date of 
the last adequate tumor assessment prior to the gap that documented 
no progression. If a new anti- cancer therap y starts prior to an event, 
the participant will be censored on the date of the last adequate 
tumor assessment that documented no progression prior to start of 
the new anti -cancer therapy . The C I for the median DOR will be 
calculated according to Brookmey er and Crowley  method.
TTP by [CONTACT_89169] /INV
Using the Kaplan -Meier method, estimate its associated statistics on 
TTP (including the median TTP with two- sided 95% CI , the TTP 
rates at clinically meaningful timepoints with two -sided 95% CI) for 
all participants who received at least one dose of lorlatinib without 
regard to discontinuation from treatment unless death occurs, new 
anti-cancer therap y is initiated 
or extended gap in tumor assessment
is present prior to progression. TTP is defined as the time from date 
of first dose to the date of the first documented PD. 
This analy sis is based on ITT population. Participants with an event 
more than 12 weeks ([ADDRESS_676122] 42 weeks) after the last 
adequate tumor assessment will be censored on the date of the last 
adequate tumor assessment prior to the gap that documented no 
progression. If 
the participant diesbefore progression, the 
participant will be censored on the date of death. If a new anti-
cancer therap y starts prior to an event, the participant will be 
censored on the date of the las t adequate tumor assessment that 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676123] -baseline tumor assessments within 12 weeks after the 
start date will be cens ored on the start date, unless the participant
dies within 12 weeks of the start date, in which case, the patient will 
be censored on date of death. The CI for the median TTP will be 
calculated according to Brookmey er and Crowley  method, and the 
CIs for the survival function estimates at the timepoints will be 
derived using the log( -log) method.
PFS by [CONTACT_89169]/INV
Using the Kaplan -Meier method, estimate its associated statistics on 
PFS (including the median PFS with two- sided 95% CI , the PFS 
rates at clinically meaningful timepoints with two -sided 95% CI) for 
all participants who received at least one dose of lorlatinib without 
regard to discontinuation from treatment unless new anti -cancer 
therap y is initiated or an extended gap in tumor assessment is 
present prior to progression or death. PFS is defined as the time 
from date of first dose to the date of the first documented PD or 
death due to an y cause, whichever occurs first. 
This analy sis is based on ITT population. Participants with an event 
more than 12 weeks ([ADDRESS_676124] 42 weeks) after the last 
adequate tumor assessment will be censored on the date of the last 
adequate tumor assessment prior to the gap that documented no 
progression. If a new anti
-cancer therap y starts prior to an event, the 
participant will be censored on the date of the last adequate tumor 
assessment that documented no progression prior to start of the new 
anti-cancer therap y. Participants with inadequate baseline 
assessment or with no adequate post
-baseline tumor assessments
within 12 weeks after the start date will be censored on the start 
date, unless the participant dies within 12 weeks of the start date, in 
which case, death will be an event on date of death. The CI for the 
median PFS will be calculated according to Brook meyer and 
Crowley  method, and the CI s for the survival function estimates at 
the timepoints will be derived using the log( -log) method .
9.4.2. Safety Analyses
All safet y anal yses will be performed on the Safety  Population.
Drug exposure will be summarized using descriptive statistics.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 57All AEs will be coded using the Medical Dictionary  for Regulatory  Activities
(MedDRA ). The investigator will classify  the severity  of AEs using the CTCAE v4.03. A 
treatment emergent AE (TEAE) is defined as an y event that occurs for the first time during 
the on- treatment period or AEs that were observed prior to the start of study treatment but 
increased in severit y during the on -treatment period. Only  TEAEs with an onset date prior to 
date of last dose + 28 days or the date of initiation of a new anti-cancer therapy  (whichever 
occurs first) will be tabulated in summary  tables. All data will be listed.
The number and percentage of participants with AEs will be summarized by  [CONTACT_53157], preferred term, relationship to study intervention , and severit y. A b y-
participant listing will be provided for those participants who experience an SAE, including 
death, or experience an AE associated with discontinuation of study  intervention .
9.5.Interim Analyses
No interim anal ysis isplanned for this study .
9.5.1. Data Monitoring Committee (DMC)
This study  will not use a data monitoring committee.
9.5.2. Independent Central Radiological Review
An independent core imaging laboratory  will be used in this study . All sites will be required 
to submit im ages to the core imaging laboratory for I CR as soon as they  are performed at the 
site so that imaging scans may  be read in real time. The requirements of submitting images 
will be provided to sites by  [CONTACT_448312] .
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 5810. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable International Conference on Harmonisation ( ICH)Good Clinical P ractice 
(GCP) Guidelines
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CF, SmPC, and other relevant documents (eg, 
advertisements) must be reviewed and approved by [CONTACT_20002] I RB/IEC 
by [CONTACT_20003] b y the IRB/IEC before the study  is initiated.
Any amendments to the protocol will require IRB/I EC approval before implementation of 
changes made to the study design, except for changes necessary  to elimin ate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC annually  or 
more frequently in accordance with the requirements, policies, and proc edures 
established by  [CONTACT_1201]/IEC.
Notify ing the IRB/IEC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures.
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, th e IRB/IEC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations.
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the wo rld, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately.
In addition, the investigator will inform [COMPANY_007] immediately  ofany urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 5910.1.2. Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investi gators are responsible for providing information on financial interests during the 
course of the stud y and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions 
regarding the stud y.
Participants must be informed that their participation is voluntary . Participants or 
their legally  authorized representative will be required to sig n a statement of informed 
consent that meets the requirements of [ADDRESS_676125] (HIPAA) requirements, where 
applicable, and the IRB/IEC or study  center.
The investigator mus t ensure that each study  participant is fully  informed about the 
nature and objectives of the study , the sharing of data related to the study  and possible 
risks associated with participation, including the risks associated with the processing 
of the partic ipant’s personal data. The participant must be informed that his/her 
personal stud y-related data will be used by  [CONTACT_78271]. The level of disclosure must also be explained to the participant.
The participant mu st be informed that his/her medical records may  be examined by  
[CONTACT_171138], by  [CONTACT_6667]/IEC members, and by  [CONTACT_55894].
The investigator furth er must ensure that each study  participant is fully  informed 
about his or her right to access and correct his or her personal data and to withdraw 
consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study .
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 6010.1.4. Data Protection
All pa rties will comply  with all applicable laws, including laws regarding the 
implementation of organizational and technical measures to ensure protection of 
participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic 
and/or paper form and will be password protected or secured in a locked room to 
ensure that onl y authorized study staff have access.  The study site will implement 
appropriate technical and organizational measures to ensure that the personal data can 
be re covered in the event of disaster.  In the event of a potential personal data breach, 
the study  site shall be responsible for determining whether a personal data breach has 
in fact occurred and, if so, providing breach notifications as required b y law.
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical 
code. An y participant records or datasets that are transferred to the sponsor will 
contain the numerical code; participant names will not be transferred. All other 
identifiable data transferred to the sponsor will be identified by  [CONTACT_20007], 
participant -specific code. The study  site will maintain a confidential list of 
participants who par ticipated in the study , linking each participant’s numerical code 
to his or her actual identity . In case of data transfer, the sponsor will protect the 
confidentiality  of participants’ personal data consistent with the Clinical Study  
Agreement and applicab le privacy  laws. 
10.1.5. Committees Structure
See Section 9.5.2 .
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on 
www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com , and other public registries in accordance with 
applicable loc al laws/regulations. In addition, [COMPANY_007] reports study  results outside of the 
requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanc ed, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
intervention al studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographical location in which the study is conducted.  US Basic 
Results are generall y submitted for posting within 1 year of the primary completion date 
(PCD) for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676126]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007] -sponsored 
interventional studies that are in scope of EU r equirements. EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (Clinical Study Report [CSR] sy nopses in which any  
data that could be used to identify  individual participants have been removed) on 
www.pfizer.com for [COMPANY_007] -sponsored interventional studies at the same time the US Basic 
Results document is posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy 0070, the proactive publication of clinical 
data to the EMA website. Clinical data, un der Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods.  Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data.  Policy 0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedu re since 01 July 2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses.  Research teams must include a biostatistician.  Data will not 
be provided to applicants with significant conflicts of interest, includin g individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electronically  (eg, laboratory  data). The 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676127] by  
[CONTACT_55896] y or electronically  signing the CRF.
The investigator must maintain accurate documentation (source data) that supports 
the information en tered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in 
encry pted electronic and/or paper form and are password protected or secured in a 
locked room to prevent access b y unauthorized third parties.
The investi gator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
This verification may  also occur after study  completion. I t is important that the 
investigator(s) and their relevant personnel are available during the monitoring visits 
and possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site 
monitoring) are provided in the c linical monitoring plan.
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authoriz ed site personnel are accurate, complete, and 
verifiable from source documents; that the safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this 
study  must be retained by  [CONTACT_1732] [ADDRESS_676128] ensure that the records continue to 
be stored securel y for so long as they  are maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_521283] l systems.
The investigator(s) will notify  sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will 
cooperate with sponsor or its agents to prepare the investigator site for t he inspection 
and will allow sponsor or its agent, whenever feasible, to be present during the 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 63inspection.  The investigator site and investigator will promptly  resolve any  
discrepancies that are identified between the stud y data and the participant's medical 
records.  The investigator will promptly  provide copi[INVESTIGATOR_475287].  Before response submission to the regulatory  authorities, the 
investigator will provide sponsor or its agents with an opportunity  to review and
comment on responses to any  such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the clinical monitoring 
plan.
10.1.9. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the st udy at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to contract 
research organization (CRO) if requested to do so by  [CONTACT_22846]/IEC or if such 
termination is required to protect the health of Study  Participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by  [CONTACT_093]
Discontinuation of further study  intervention development
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol the contract will control as to termination rights.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 6410.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
Investigator after publication of the overall study  results or one y ear after end of the 
study (or stud y termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent 
publications such as secondary  manuscripts, and submit all manuscripts or abstracts 
to the sponsor [ADDRESS_676129], remove an y previously  undisclosed confidential information before 
disclosure, except for any stud y-or [COMPANY_007] intervention -related in formation necessary  
to the appropriate scientific presentation or understanding of the stud y results.
For all publications relating to the stud y, the Investigator will compl y with recognized 
ethical standards concerning publications and authorship, including those established 
by [CONTACT_4717].
The sponsor will comply  with the requirements for publication of the overall study  
results covering all Investigator sites. In accordance with standard editorial and 
ethical practice, the sponsor will support publication of multicenter studies only  in 
their entiret y and not as individual site data. In this case, a coordinating investigator 
[INVESTIGATOR_159828] b y mutual agreement.
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors 
authorship requirements.
If publication is addressed in the clinical study  agreement, the publication policy  set 
out in this section wi ll not apply .
10.1.11. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_505858].
To facilitate access to appro priatel y qualified medical personnel on stud y-related medical 
questions or problems, participants are provided with a contact [CONTACT_1137].  The contact [CONTACT_95504], at a minimum, protocol and investigational product identifiers, participant study  
numbers, conta ct information for the investigator site, and contact [CONTACT_4664] a contact [CONTACT_475350] a medical 
question or problem originating from another healthcare professional not invol ved in the 
participant’s participation in the study .  The contact [CONTACT_74073]; however, it should be used 
only in the event that the established communication pat hway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or prob lems that may arise during the study .  For sites other than 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 65a [COMPANY_007] clinical research unit (CRU), the contact [CONTACT_521298] y, and if a participant calls that number, he or she will be directed back to 
the invest igator site.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 6610.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 4will be performed b y the local laboratory .
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5of the protocol.
Additional tests may  be performed at an y time during the stud y as determined necessary 
by [CONTACT_43215].
Pregnancy  Testing 
Refer to Section 5.1Inclusion Criteria for screening pregnancy  criteria.
For details of timing of recommended pregnancy  testing see Section 8.2.6
Table 4. Protocol Required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
Hem atologyPlatelet Count
Hem oglobinWhite blood cell (WBC) count w ith Differential :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Clinical 
Chemistry1Blood urea 
nitrogen (BUN) or 
UreaPotassium Aspartate 
Aminotransferase
(AST)Total bilirubin
Creatinine Sodium Alanine 
Aminotransferase
(ALT)Phosphorus or 
Phosphate
Glucose (fasting) Total Calcium Alk Phos Serum total 
amylase2
Uric Acid Magnesium Albumin Serum lipase
Other Screening 
TestsHighly sensitive serum or urine human chorionic gonadotropin (hCG) pregnancy 
test (as needed for w omen of childbearing potential)
Lipi[INVESTIGATOR_805]:  Total Cholesterol, low density lipoproteins ( LDL ), high density 
lipoproteins ( HDL ), Triglycerides.
The results of each test must be entered into the CRF at screening only or C1D1 if 
baseline assessment not performed within 7 days before.
NOTES:
1.Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver 
stoppi[INVESTIGATOR_31777] 7.1and Appendix 6. All events of ALT 3 × upper limit of 
norm al (ULN) and bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 67Table 4. Protocol Required Safety Laboratory Assessments
norm alized ratio (INR) >1.5, if INR measured which may indicate severe liver injury (possible Hy’s Law), 
must be reported as an SAE (excluding studies of hepatic impairment or cirrhosis).
[ADDRESS_676130] document their review of each laboratory  safet y report .
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 6810.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (ie, not related 
to progression of underl ying disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnose d after study  intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
“Lack of efficacy ” or “failure of expected pharmacological action” per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy will be reported as AE or SAE if they  fulfil the definition of an AE 
or SAE.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 69Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying dise ase, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected f or the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hos pi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
Worsening of signs and symptoms of the malignancy  under study  should be 
recorded as AEs in the appropriate section of the CRF.  Disease progression 
assessed b y measurement of malignant lesions on radiographs or other methods 
should not be reported as AEs.
10.3.2. Definition of SAE
If anevent is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre- existing c ondition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 70The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to i nclude experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be imme diatel y life-threatening or result in death or hospi[INVESTIGATOR_402880]. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency or drug abuse.
Progression of the malignancy  under stud y (including signs and s ymptoms of 
progression) should not be reported as an SAE unless the outcome is fatal within 
the active collection period.  Hospi[INVESTIGATOR_185569] s ymptoms of disease
progression should not be reported as an SAE.  If the malignancy  has a fatal 
outcome during the study or within the active collection period, then the event 
leading to death must be recorded as an AE on the CRF, and as an SAE with 
Common Terminology  Crite ria for Adverse Events (CTCAE) Grade 5 (see the 
Severity  Assessment section).
10.3.3. Recording/Reportin gand Follow -Up of AE and/or SAE
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF
and for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse Event 
(SAE) Report Form to [COMPANY_007] Safety .  These requirements are delineated for 3 ty pes of 
events: (1) SAEs; (2) non -serious adverse events (AEs); and (3) exposure to the
investigational product under study  during pregnancy  or breastfeeding, and occupational 
exposure.  
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676131] 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureNone All (And exposure during 
pregnancy [EDP ]
supplemental form for 
EDP)  
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostics 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of CT S AE Report Form
/AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories:
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 72GRADE Clinical Description of Severit y
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 LIFE -THREATENING consequences; urgent intervention indicated
5 DEATH RELATED TO adverse event
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurr ed and the investigator has 
minimal information to include in the initial report to the sponsor . However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 73If the investigator does not know whether or not the investigational product caused 
the event, then the event will be handled as “related to investigational product” for 
reporting purposes, as defined by  [CONTACT_456]" and "In addition , if the investigator 
determines that an SAE is associated with study  procedures, the investigator must 
record this causal relationship in the source documents and CRF, and report such 
an assessment in the dedicated section of the CT SAE Report Form and in
accordance with the SAE reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other health care 
professionals.
New or updated informatio n will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event with in 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes t o existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 74Contacts for SAE reporting can be found in the investigator site file.
SAE Reporting to [COMPANY_007] Safety via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to [COMPANY_007] Safety .
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by 
[CONTACT_22855].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in the investigator site file.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 7510.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal fem ale with 1 of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen i nsensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above conditions can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
3.Postmenopausal female
A postmenopausal state is defined as age 60 or older or no menses for 12 months 
without an alternative medical cause.
A high follicle stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therap y (HRT).
Females on HRT and whose menopausal status is in doubt will be required to use 
one of the non -estrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y. Otherwise, they must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment .
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
P F -0 6 4 6 3 9 2 2 ( L orlati ni b) 
B 7 4 6 1 0 2 7 
Fi nal Pr ot oc ol, 2 2 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 7 6 C o ntrace pti o n G ui da nce: 
C o ntr ace pti o n ––f or w o me n 
Fe male partici pa nts m ust use hi g hl y effecti ve c o ntrace pti o n w hile ta ki n g st u d y  i nter ve nti o n 
a n d f or at least [ADDRESS_676132] u d y i nter ve nti o n. 
L orlati ni b ma y  re d uce t he effecti ve ness of h or m o nal c o ntrace pti ve met h o ds; t heref ore, 
h or m o nal c o ntrace pti ves ma y  n ot be c o nsi dere d hi g hl y effecti ve. If h or m o nal c o ntrace pti o n 
is u na v oi da ble it m ust be use d i n c o m bi nati o n wit h a c o n d o m. 
Hi g hl y Effecti ve Met h o ds T h at H a ve L o w User De pe n de nc y 
1. I ntra uteri ne de vice (I U D). 
2. Bilateral t u bal occl usi o n. 
3. Vasect o mize d part ner .
Vasect o mize d part ner is a hi g hl y effecti ve c o ntrace pti ve met h o d pr o vi de d t hat 
t he part ner is t he s ole se x ual part ner of t he W O C B P a n d t he a bse nce of s per m 
has bee n c o nfir me d.  If n ot, a n a d diti o nal hi g hl y effecti ve met h o d of 
c o ntrace pti o n s h o ul d be use d.  T he s per mat o ge nesis c y cle is a p pr o xi matel y  9 0 
da y s. 
C o ntr ace pti o n ––f or me n 
Male partici pa nts m ust use a c o n d o m w hile ta ki n g st u d y i nter ve nti o n a n d f or a t least [ADDRESS_676133] u d y  i nter ve nti o n. 
C ollecti o n of Pre g na nc y  I nf or mati o n: 
F or b ot h u na p pr o ve d/ u nlice nse d pr o d ucts a n d f or mar kete d pr o d ucts, a n E D P occ urs if: 
A fe male bec o mes, or is f o u n d t o be, pre g na nt eit her w hile recei vi n g or ha vi n g 
bee n e x p ose d (e g, beca use of treat me nt or e n vir o n me ntal e x p os ure) t o t he st u d y  
i nter ve nti o n ; or t he fe male bec o mes or is f o u n d t o be pre g na nt after disc o nti n ui n g 
a n d/ or bei n g e x p ose d t o t he st u d y  i nter ve nti o n ;
A n e xa m ple of e n vir o n me ntal e x p os ure w o ul d be a case i n v ol vi n g direct 
c o ntact wit h a [COMPANY_007] pr o d uct i n a pre g na nt w o ma n (e g, a n urse re p orts t hat s he 
is pre g na nt a n d has bee n e x p ose d t o c he m ot hera pe utic pr o d ucts). 
A male has bee n e x p ose d (e g, beca use of treat me nt or e n vir o n me ntal e x p os ure) t o 
t he st u d y  i nter ve nti o n pri or t o or ar o u n d t he ti me of c o nce pti o n a n d/ or is e x p ose d 
d uri n g his part ner’s pre g na nc y . 
If a partici pa nt or partici pa nt’s part ner bec o mes or is f o u n d t o be pre g na nt d uri n g t he 
partici pa nt’s treat me nt wit h t he st u d y  i nter ve nti o n , t he i n ves ti gat or m ust re p ort t his 0 9 0 1 7 7 e 1 9 2 a 9 4 2 1 3\ A p pr o v e d\ A p pr o v e d O n: 2 7- J a n- 2 0 2 0 1 0: 5 6 ( G M T) 
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676134] in a pregnant woman (eg, a 
participant reports that she is pregnant and has been exposed to a cytotoxic product b y 
inhalation or spi[INVESTIGATOR_4598]) to [COMPANY_007] Safety using the EDP supplemental form.  This must be done 
irrespective of whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The information submitted should include the anticipated date of delivery  (see 
below for information related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregna ncy and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminate d fetus should be assessed by  [CONTACT_4692] (unless pre -
procedure test findings are conclusive for a congenital anomaly  and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontane ous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional infor mation about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_676135] 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention .
Additional information regarding the EDP may  be requested by  [CONTACT_521299].  Further follow -
up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on preterm 
infants to identify  developmental delay s). In the case of paternal exposure, the investigator 
will provide the participant with the Pregnant Partner Release of Information Form to deliver 
to his partner.  The investigator must document in the source documents that the participant 
was given the Pregnant Partner Release of Information Form to provide to his partner.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 7810.5. Appendix 5: RECIST ( version 1.1) Tumor Assessment Criteria21
Atbaseline, individual tumor lesions will be categorized by  [CONTACT_521300], according to the criteria summarized below:
Measurable Lesions
Lesions that can be accurately  measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of: 
[ADDRESS_676136] scan (CT scan slice 
thickness no greater than 5 mm)
10 mm for lesions assessed clinically b y caliper measurement (lesions which cannot 
be accuratel y measured with calipers should be recorded as non -measurable).
[ADDRESS_676137] X -ray.
[ADDRESS_676138] scan (CT scan slice 
thickness recommended to be no greater than 5 mm). 
Non-measurable Lesions 
Non-measurable lesions include small lesions (longest diameter <10 mm or pathological 
lymph nodes with a ≥ 10 but < 15 mm short axis) as well as t ruly non -measurable lesions.  
Truly  non-measurable lesions include: leptomeningeal disease, ascites, pleural or pericardial 
effusion, inflammatory  breast disease, ly mphangitic involvement of skin or lung, abdominal 
masses identified b y physical exam and no t measurable b y reproducible imaging techniques.
Nodes that have a short axis <10 mm are considered non- pathological and should not be 
recorded or followed. 
Special Considerations Regarding Specific Lesions 
Bone lesions:
Bone scan, positron emission tomo graph y (PET)scan or plain films are not 
considered adequate imaging techniques to measure bone lesions.  However, these 
techniques can be used to confirm the presence or disappearance of bone lesions.
Lytic bone lesions or mixed ly tic-blastic lesions, wit h identifiable soft tissue 
components, that can be evaluated b y cross sectional imaging techniques such as CT 
or MRI  can be considered as measurable lesions if the soft tissue component meets 
the definition of measurability  described above.
Blastic bone le sions are non -measurable. 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 79Cystic lesions:
Lesions that meet the criteria for radiographicall y defined simple cy sts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they  
are, b y definition, simple cy sts.
‘Cystic l esions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability  described above.  
However, if non- cystic lesions are present in the same patient, these are preferred for 
selection as targ et lesions.
Lesions with prior local treatment:
Tumor lesions situated in a previousl y irradiated area, or in an area subjected to other 
loco- regional therap y, are usually not considered measurable unless there has been 
demonstrated progression in the lesion.
Solitary lesions:
If a measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology . 
Recording Tumor Measurements
All measurable lesions up to a maximum of 2 lesions per organ and up to 5 in to tal and 
representative of all involved organs should be identified as target lesions and measured and 
recorded at baseline and at the stipulated intervals during treatment.  Target lesions should be 
selected on the basis of their size (lesions with the lon gest diameters) and their suitability  for 
accurate repetitive measurements (either b y imaging techniques or clinically). 
The longest diameter will be recorded for each target lesion.  The sum of the longest 
diameter of all target lesions will be calculate d and recorded as the baseline sum diameter to 
be used as reference to further characterize the objective tumor response of the measurable 
dimension of the disease during treatment. 
One exception to the above described approach is related to pathological lymph nodes.  
Pathological l ymph nodes are defined as measurable lesions and may  be identified as target 
lesions if the criterion of a short axis of ≥ [ADDRESS_676139] in which the image is obtained (for CT scan this is almost always the 
axial plane; for MRI  the plane of acquisition may  be axial, sagittal or coronal).  The smaller 
of these measures is the short axi s. 
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum diameters.  The baseline 
sum diameters will be used as reference to further characterize an yobjective tumor 
regression in the measurable dimension of the disease.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 80All other lesions (or sites of disease) should be identified as non -target lesions and should 
also be recorded at baseline.  Measurements are not required and these lesions should be 
followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’.  In addition, it is 
possible to record multiple non -target lesions involving the same organ as a single item on 
the case record form (eg ‘multiple enlarged pelvic ly mph nodes’ or ‘ multiple liver 
metastases’).
Definition of Tumor Response 
Target Lesions
Response in target lesions is defined as follows:
Complete Response (CR): disappearance of all target lesions. 
Partial Response (PR): at least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.
Progressive Disease (PD): at least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study  (this includes the baseline sum 
if that is the smallest on study ).  In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5 mm.  The appearance of one 
or more new lesions is also considered a sign of pro gression.
Stable Disease (SD): neither sufficient shrinkage to qualify  for PR nor sufficient 
increase to qualify  for PD, taking as reference the smallest sum diameters while on 
study .
When nodal disease is included in the sum of target lesions and the node s decrease to 
‘normal’ size (<10 mm), they  may  still have a measurement reported on scans.  This 
measurement should be recorded even though the nodes are normal in order not to overstate 
progression should it be based on increase in size of the nodes.  As noted earlier, this means 
that patients with CR may not have a total sum of ‘zero’ on the CRF.
Non-Target Lesions
While some non -target lesions may  actually  be measurable, they  need not be measured and 
instead should be assessed only  qualitativel y at the t ime points specified in the protocol. 
Response in non -target lesions is defined as follows:
Complete Response (CR): Disappearance of all non -target lesions and normalization 
of tumor marker level. All ly mph nodes must be non-pathological in size (<10 mm 
short axis).
Non-CR/Non -PD: Persistence of one or more non -target lesion(s) and/or 
maintenance of tumor marker level above the normal limits. 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 81Progressive Disease (PD): Unequivocal progression of existing non -target lesions. 
(Note: the appearance of one or more new lesions is also considered progression).
Cytology, histology 
These techniques can be used to differentiate between PR and CR in rare cases if required by  
[CONTACT_990] (for example, residual lesions in germ cell tumors).  When effusions are known to 
be a potential adverse effect of treatment (eg taxane compounds or angiogenesis inhibitors), 
the cy tological confirmation of the neoplastic origin of any  effusion that appears or worsens 
during treatment can be considered if the measurable tumor has met cr iteria for response or 
stable disease in order to differentiate between response or stable disease and progressive 
disease.
For patients having effusions or ascites, only  cases having cy tological proof of malignancy  
should be recorded on the CRF.  Effusion s that have not been evaluated using cy tology  or 
were found to be non -malignant should not be recorded on the CRF. 
New Lesions 
The appearance of new malignant lesions indicates PD. New lesion should be unequivocal 
(eg not attributable to differences in imaging technique, or change in imaging modalit y or 
findings not attributable to tumor). If a new lesion is equivocal, for example due to its small 
size, continued therap y and follow -up assessment will clarify  the etiology  of the disease. If 
repeat scans co nfirm there is definitely  a new lesion, then progression should be declared 
using the date of the initial scan. 
The use of fluorodeoxy glucose (FDG )-PET is sometimes reasonable to complement a CT 
scan assessment of a PD (particularl y for possible ‘new’ dis ease).  New lesions on the basis 
of FDG -PET imaging can be identified according to the following algorithm: 
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up 
No FDG -PET at baseline and a positive FDG- PET at follow -up: if the positive 
FDG-PET at follow -up corresponds to a new site of disease confirmed by  [CONTACT_4654], this is 
PD.
If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT scans are needed to determine if there is trul y progression occurring 
at that site (if so, the date of PD will be the date of the initial abnormal FDG -PET scan).
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT that 
is not progressing on the basis of the anatomic images, this is not PD.
Confirmation of Tumor Response 
Confirmation of response is required for non -randomized trials with primary  endpoint of 
response, but is not required in randomized studies since the control arm serves as 
appropriate means of interpretation of da ta.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676140] v 1.1 
When both target and non -target lesions are present, individual assessments will be recorded 
separately . The overall assessment of response will involve all parameters as depi[INVESTIGATOR_50392] 5.
Table 5. Response Evaluation Criteria in Solid Tumors
Target lesions Non-target lesions New
LesionsOverall
response
CR CR No CR
CR Non-CR/non -PD No PR
CR Not evaluated No PR
PR Non-PD or
not all evaluatedNo PR
SD Non-PD or
not all evaluatedNo SD
Not all
evaluatedNon-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease,
PD = progressive disease, and NE = inevaluable.
Best overall response
The best overall response is determined once all the data for the patient is known.  Best 
response in trials in which confirmation of complete or partial response is not required (ie. 
randomized trials) is defined as the best response across all time points (for example, a 
patient who has SD at first assessment, PR at second assessment, and PD on last assessment 
has a best overall response of PR).  When SD is believed to b e the best response, it must also 
meet the protocol specified minimum time from baseline.  If the minimum time is not met 
when SD is otherwise the best time point response, the patient’s best response depends on the 
subsequent assessments.  For example, a patient who has SD at first assessment, PD at 
second and does not meet minimum duration for SD, will have a best response of PD.  The 
same patient lost to follow -up after the first SD assessment would be considered non-
evaluable. 
When confirmation of CR a nd PR is required (ie, non -randomized trials with primary  
endpoint of response), the best overall response is defined according to the tumor response 
along the stud y.  Complete or partial responses may be claimed onl y if the criteria for each 
are met at a following time point as specified in the protocol (generall y 4 weeks later).
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
‘symptomatic deterioration’.  Every  effort should be made to document objective progression 
even after discontinuation of treatment.  S ymptomatic deterioration is not a descriptor of an 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 83objective response: it is a reason for stoppi[INVESTIGATOR_45806] .  The obj ective response status of 
such patients is to be determined b y evaluation of target and non -target lesions.
In some circumstances it may  be difficult to distinguish residual disease from normal tissue.  
When the evaluation of CR depends upon this determina tion, it is recommended that the 
residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) before assigning a status of 
complete response.  FDG -PET may  be used to upgrade a response to a CR in a manner 
similar to a biopsy  in cases where a residual radi ographic abnormality  is thought to represent 
fibrosis or scarring.  
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 8410.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments 
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a 
more serious potential o utcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who experience a transaminase elevation above 3 times the 
upper limit of normal (× ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin ( TBili) elevations (>2 × ULN) b y several 
days or weeks.  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 × ULN (ie, AST/AL T and TBili values will be elevated within the same lab sample).  
In rare instances, b y the time TBi li elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potentia lDILI (assessed per Hy’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For participants with baseline AST OR ALT OR TBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at le ast 1 × ULN or if the value reaches >3 × ULN 
(whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. The participant 
should return to the investigator site and be evaluated as soon as possible, preferabl y within 
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 8548 hours from awareness of the abnormal results.  This evaluation should include la boratory  
tests, detailed history , and phy sical assessment.  The possibility  of hepatic neoplasia (primary  
or secondary ) should be considered.
In addition to repeating measurements of AST and AL T and TBili for suspected cases of 
Hy’s Law, additional laborat ory tests should include albumin, creatine kinase (CK), direct 
and indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time 
(PT)/international normalized ratio (I NR), total bile acids, and alkaline phosphatase. 
Consideration should also be gi ven to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , includi ng relevant information, such as review of ethanol, 
acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact [CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infec tion and liver imaging 
(eg, biliary  tract) and collection of serum sample for acetaminophen drug and/or protein 
adduct levels may  be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defin ed above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the liver function test ( LFT)abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the r esults of the investigations performed to determine etiology of the LFT 
abnormalities.  
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 8610.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events (AEs)
Marked sinus brady cardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >220 msec.
New prolongation of QTcF to >470 m sec (absolute) or by60msec from 
baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate <120 bpm.
New -onset ty peI second -degree (Wenckebach) AV block of >30 seconds’ 
duration.
Frequent premature ventricular complexes (PVCs), triplets, or short intervals 
(<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as Serious Adverse Events (SAEs)
QTcF prolongation >500 msec.
New ST- T changes suggestive of myocardial ischemia.
New -onset left bundle branch block (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec).
Symptomatic brady cardia.
Asystole:
In awake, s ymptom -free participants in sinus rhythm, with documented 
periods of as ystole  3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom -free participants with atrial fibrillation and brady cardia 
with [ADDRESS_676141] 5 seconds or longer. 
Atrial flutter or fibrillation ,with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = short 
duration with relevant s ymptoms or lasting >1 minute).
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 87Ventricular rh ythms >30 seconds’ duration, including idioventr icular rhy thm (rate 
<40bpm), accelerated idioventricular rh ythm (40< x <100), and 
monomorphic/poly morphic ventricular tachy cardia >100 bpm (such as torsades de 
pointes).
Type II second -degree (Mobitz II) AV block.
Complete (third- degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
Change in pattern suggestive of new m yocardial infarction.
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion.
Ventricular fibrillation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
Theenumerated list of major events of potential clinical concern are recommended as “alerts” and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 8810.8. Appendix 8: Country -specific Requirements
[LOCATION_009] specific requirements
1. GCP Training
Prior to enrollment of any  subjects, the investigator and any  sub- investigators will complete 
the [COMPANY_007] -provided Good Clinical Practice training course (“[COMPANY_007] GCP Training”) or 
training deemed equivalent by  [CONTACT_4618]. Any  investigators who later join the study  will 
complete the [COMPANY_007] GCP Training or equivalent before performing study -related duties. For 
studies of applicable duration, the investigator and sub-investigators will complete [COMPANY_007] 
GCP Training or equivalent every  three y ears during t he term of the study , or more often if 
there are significant changes to the ICH GCP guidelines or course materials.
2.Investigational Product
No subjects or third -party  payers will be charged for study  intervention .
3.Inspections
The investigator(s) will notif y [COMPANY_007] or its service provider immediatel y of any regulatory 
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with [COMPANY_007] or its service provider to prepare the study  site for the inspection and will allow 
[COMPANY_007] or its service provider (if not prohibited b y law) to be present during the inspection. 
The study  site and investigator will promptly  resolve an y discrepancies that are identified 
between the stud y data and the subject's medical records. The investiga tor will promptly  
provide copi[INVESTIGATOR_265332]. Before response 
submission to the regulatory  authorities, the investigator will provide [COMPANY_007] or its service 
provider with an opportunity  to review and comment on responses to an y such findings.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 8910.9. Appendix 9: ECOG Classification of Performance Status
Score Definition
0 Fully  active, able to carry  on all pre -disease performance without restriction
1 Restricted in phy sically  strenuous activity  but ambulatory  and able to carry  
out work of a light or sedentary  nature, eg, light house work or office work
2 Ambulatory  and capable of all self -care but unable to carry  out an y work 
activities.  Up and about more than 50% of waking hours
3 Capable of onl y limited self -care, confined to bed or chair more than 50% of 
waking hours
4 Completely  disabled.  Cannot carry  on any  self-care.  Totall y confined to bed 
or chair
5 Dead
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 9010.10. Appendix 10: Abbreviations
Abbreviation Term
AE adverse event
AIDS acquired immunodeficiency  syndrome
AJCC American Joint Committee on Cancer
ALK anaplastic l ymphoma kinase
ALT alanine aminotransferase
ANC absolute neutrophils count
AST aspartate aminotransferase
AV atrioventicular
BCRP breast cancer resistance p rotein
bpm beats per minute
BID twice dail y
BUN blood urea nitrogen
CAP chest abdomen pelvis
C1D1 cycle [ADDRESS_676142] SAE clinical trial serious adverse event
CYP cytochrome P450
DCIS ductal carcinoma in situ
DDI drug-drug interaction
DILI drug-induced liver i njury
DMC data monitoring committee
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676143] European Clinical Trials Database
FDA Food and Drug Administration (United 
States)
FDG fluorodeox yglucose
FISH fluorescence in situ h ybridization
FSH follicle stimulating hormone
GCP Good Clinical Practice
GGT gamma glutam yl transferase
HBV hepatitis B virus
HBsAg hepatitis B surface antigen
hCG human chorionic gonadotropin
HCV hepatitis C virus
HDL high densit y lipoprotein
HER2 human epi[INVESTIGATOR_3506] [ADDRESS_676144]
HIV human immunodeficiency  virus
HMG CoA 3-hydroxy -3-methy lglutary l coenzy me
HRT hormone replacement therap y
IB investigator’s b rochure
ICF Informed consent form
ICH International Conference on Harmonisation
IC intracranial
IC-OR intracranial objective r esponse
IC-ORR intracranial objective response rate
IC-TTR time to intracranial response
ICR independent central review 
ID identification
IHC immunohistochemistry
ILD interstitial lung disease
IND investigational new drug application
INR international normalized ratio
INV investigator
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676145] authorization efficacy stud y
PAP pulmonary  arterial pressure
PD progression of disease
PCD primary  completion date
PET positron emission tomography
PFS progression -free s urvival
P-gp permeability  glycoprotein
PI [INVESTIGATOR_521284] i nvestigator
PR partial response
PS performance status
PT prothrombin time
PVC premature ventricular complexes
PXR human pregnane -X-receptor 
QD once dail y
QTcF Fridericia’s formula
RECI ST Response Evaluation Criteria in Solid Tumor
ROS1 c-ROS oncogene -[ADDRESS_676146] characteristics
SoA schedule of activities
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, [ADDRESS_676147] upper limit of normal
US [LOCATION_002]
WBC white blood cell 
WOCBP women of childbearing p otential
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 9411.REFERENCES
1.Center M, Siegel R, Jemal A. American Cancer Society Global Cancer: Facts & Figures. 
Atlanta, GA: American Cancer Societ y; 2011.
2.Rikova K, Guo A, Zeng Q, et al. Global survey  of phosphoty rosine signaling identifies 
oncogenic kinases in lung cancer. 2007;131(6):1190-203.
3.Soda M, Choi YL , Enomoto M, et al. I dentification of the transforming EML4- ALK 
fusion gene in non -small -celllung cancer. Nature. 2007;448(7153):561-6.
4.Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4 -ALK non -
small cell lung cancer. Eur J Cancer. 2010;46(10):[ADDRESS_676148]-line ceritinib versus platinum -based 
chemotherap y in advanced ALK -rearranged non -small -cell lung cancer (ASCEND -4): a 
randomised, open -label, phase 3 study . Lancet. 2017;389([ZIP_CODE]):917-29.
6.Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK -
Positive Non- Small -Cell Lung Cancer. N Engl J Med. 2017;377(9):829 -38.
7.
Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK- positive, crizotinib -resistant, 
non-small -cell lung cancer: a single - group, multicentre, phase 2 trial. Lancet Oncol. 
2016;17(2):23 4-42.
8.Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK -rearranged non -small -cell lung 
cancer. N Engl J Med. 2014;370(13):1189 -
97.
9.Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With Crizotinib in Patients With 
Advanced ALK -Rearranged Non- Small -Cell L ung Cancer and Brain Metastases. J Clin 
Oncol. 2015;33(17):[ADDRESS_676149]- and 
Second- Generation ALK I nhibitors in ALK -Rearranged Lung Cancer. Cancer Discov. 
2016;6(10):11 18-33.
11.
EMA website. https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq. 
Accessed 02 Jul 2019.
12.Keytruda [SmPC]. The Netherlands: [COMPANY_006] Sharp and Dohme BV; 2015.
13. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First -Line Treat ment of 
Metastatic Nonsquamous NSCL C. N Engl J Med. 2018;378(24):2288 -
301.
14.Reck M, Rodriguez -Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherap y 
for PD -L1-Positive Non- Small -Cell L ung Cancer. N Engl J Med. 2016;375(19):1823 -33.
15.National Center for Complementary  and Integrative Health. 
https://nccih.nih.gov/health/providers/digest/herb -drug.  Accessed 28 Jun 2019.
16.Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid -lowering drugs: 
mechanisms and clinical relevance. Clin Phar macol Ther. 2006;80(6):565 -81.
17.Miller M. “What Are the Effects of Statins on Triglycerides and What Are the Results of 
Major Outcomes Studies?” 2009 Mar 12; http://www.medscape.org/viewarticle/589010.
18.Kajinami K, Takekoshi N, Saito Y. Pi[INVESTIGATOR_2830]: efficacy  and safet y profiles of a novel 
synthetic HMG -CoA reductase inhibitor. Cardiovasc Drug Rev. 2003;21(3):199-215.
19.Schaefer EJ, McNamara JR, Tay ler T, et al. Comparisons of effects of statins 
(atorvastatin, fluvastatin, lovastatin, pravastatin, a nd simvastatin) on fasting and postprandial 
lipoproteins in patients with coronary  heart disease versus control subjects. Am J Cardiol. 
2004;93(1):31 -9.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)
PF-06463922 (Lorlatinib)
B7461027
Final Protocol, 22 January 2020
PFIZER CONFIDENTIAL
Page 9520.Lin JJ, Schoenfeld AJ, Zhu VW, et al. Efficacy  of platinum -pemetrexed combination 
chemotherap y in A LK+ non -small cell lung cancer refractory  to second -generation ALK 
TKIs. American Societ y of Clinical Oncology ; 2019.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECI ST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
090177e192a94213\Approved\Approved On: 27-Jan-2020 10:56 (GMT)